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ABSTRACT 
Bone tissue engineering is an attractive alternative to transplanting harvested tissue for 
bone defect repair. Various signals are involved in the regulation of stem/progenitor cell 
behavior, development and healing, which could be beneficially utilized in bone tissue 
engineering. However, bone tissue engineering research has very limited success in 
translation into the clinic, which often stems from the inappropriate administration of these 
signaling molecules due to the lack of optimal delivery systems. Therefore, this project is 
aimed at the development of new approaches to bone tissue engineering by mimicking 
advantageous features of the native extracellular matrix and signaling processes involved 
in development and natural healing. 
The author first develops preprogrammed drug delivery systems to achieve long-term 
pulsatile delivery of parathyroid hormone (PTH). A series of techniques, including 
polymer synthesis, drug formulation and device fabrication are developed to control the 
physical and chemical properties of the delivery devices so as to achieve spatiotemporal 
controlled drug release. Systemic pulsatile PTH release from the delivery device is 
demonstrated to increase bone volume and mineralized bone density, thereby providing a 
promising complying-friendly alternative to the standard daily PTH injection treatment for 
osteoporosis. Then PTH is repurposed successfully for local bone regeneration in a mouse 
calvarial bone defect regeneration model by using the pulsatile delivery system in 
combination with a biomimetic nanofibrous PLLA scaffold developed in our lab. Such 
 xiv 
system could possibly be utilized to regenerate various bone defects. 
Considering that the native bone defect healing process is initiated by macrophages via 
engulfing dead cells, the author develops a novel bioconjugation strategy to fabricate 
biodegradable microspheres to mimic apoptotic cells to target macrophages to initiate a 
biomimetic bone healing process. The biodegradable apoptotic cell-mimicking 
microspheres (BAM) are decorated with “eat me signal” and are shown to significantly 
enhance macrophage phagocytosis and enhance bone marrow stromal cell (BMSCs) 
migration via increased secretion of chemokines. Implanting a 3D space-defining 
biomimetic nanofiberous (NF) scaffold loaded with BAM results in a drastic increase in 
endogenous mesenchymal stem/progenitor cell recruitment into the scaffold compared to 
the same scaffold loaded with control microspheres, leading to critical-sized bone defect 
repair. This novel biomimetic approach opens a potential new avenue for bone 
regeneration without the need for exogenous cells. 
 1 
 
 
CHAPTER 1 
Bone Tissue Engineering 
 
1.1 Introduction  
Bone loss or damage can result from various causes including degenerative disease, 
surgery, and trauma, and significantly compromises patient quality of life[1, 2]. Generally 
bone possesses an intrinsic ability to self-repair, but there are many situations where 
complete bone regeneration cannot occur and needs to be stimulated[3]. Millions of 
patients suffering from bone defects require bone grafts and substitutes procedure. The 
bone grafts and substitutes market was valued at over USD 2.3 billion in 2015 and is 
expected to reach over USD 3.6 billion between 2016 and 2024[4]. Currently, the standard 
bone-grafting approach widely used in clinical practice is autologous, allogeneic or 
xenogeneic[5, 6].  Autologous bone grafting is considered the gold standard treatment, in 
which host bone is removed from another site to fill the defect. However, many limitations 
remain including multiple required surgeries, potential morbidity and the limited quantity 
of donor tissues[7-9]. Allogeneic or xenogeneic graft, the transplantation of bone tissue 
from another human or species donors, is an optional treatment but has inherent limitations 
including immunogenic responses, infection risks and pathogen transmission[10-13]. For 
these reasons, an alternative approach, bone tissue engineering, has emerged as a potential 
new therapy. The tissue engineering approach utilizes biomaterials to provide the 
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microenvironment for regenerative cells, supporting cell attachment, proliferation, 
differentiation and tissue synthesis[14, 15]. While osteogenic scaffolds have been 
developed, they have not yet been sufficient to robustly regenerate high quality bone[16, 
17].  The addition of stem and/or progenitor cells has proved to initiate and promote 
improved and/or faster bone healing[18-22]. Cell-based therapies are very promising to 
enhance bone regeneration but suffer major limitations such as the source of cells, the in 
vitro manipulation, the rigorous regulatory approval process and associated high costs[23-
25]. Acellular biomaterials are emerging to overcome the need for addition of external 
cells. Such cell-free system require advanced biomimetic approaches, which draw on 
biological knowledge and engineering tools to mimic and replicate the certain 
advantageous features of the natural extracellular matrix (ECM). At the same time some 
artificially engineered features can be incorporated so as to stimulate and accelerate the 
regeneration process[14, 26, 27].  
In many situations (e.g. large defect repair, impaired tissue function), endogenous signal 
cues are usually not sufficient in type and/or amount, thus the addition of exogenous signal 
cues is necessary. The biomimetic drug delivery strategy aims to deliver signal cues, 
mimicking the signaling process of the natural bone healing and to accelerate bone repair 
and regeneration[24, 28].  
1.2 Scientific Challenges and Significance 
Growth factors (GFs) are one important group of signal molecules, which have been 
intensively studied. A multitude of growth factors are involved in regulating the bone 
regeneration process and some have demonstrated great potential in numerous preclinical 
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studies. However, the promising outcomes achieved in the animal models have only 
partially been translated to human, mainly due to their side effects and safety issue 
including systemic hypotension and edema, heterotopic bone formation and increased 
cancer risk. Besides growth factors, other types of signal molecules have exhibited 
attractive potential in bone tissue engineering applications.  
One example is Parathyroid Hormone (PTH), an endocrine secretion molecule, which is a 
key regulator of the bone remolding process[29]. Its efficacy, minor side effects in 
improving bone micro-architecture, mineral density and reducing fractures has been well 
established and demonstrated in multiple clinical trials [30]. PTH needs to be delivered at 
specific time points and follow a certain release pattern in order to exert the desired 
therapeutic effects[31]. While the majority of drug delivery systems developed thus far can 
achieve a prolonged and sustained delivery, there has been limited progress in designing 
controlled release systems to couple the spatiotemporal sensitivity of a patient to PTH to 
enable or optimize its therapeutic effect[32].  
Another important group of signal molecules are the membrane lipid molecules, which are 
widely involved in cell-cell recognition and interaction, thus regulating the tissue 
development process[33, 34].  Due to the hydrophobic structure of the lipids, most of lipid 
molecules are formulated into liposome, and administered systemically[35, 36]. However, 
systemic liposome treatments have several disadvantages[37, 38] including instability in 
the blood stream, short half-lives and off-target effects. This route of administration is 
suitable for localized defect repair, which often requires spatially-controlled and prolonged 
presentation of the signal cues. 
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1.3 Aims and Dissertation Overview 
The main hypotheses of this thesis are: 1. An implantable delivery device capable of long-
term PTH pulsatile delivery can be developed and the engineered PTH release can promote 
bone growth systemically; 2. PTH can be repurposed for local bone defect repair. The 
pulsatile release promotes bone regeneration whereas the continuous release inhibits bone 
regeneration. The local release is advantageous over the standard systemic injection in 
repairing local defects; 3. Biodegradable apoptotic-cell mimicking (BAM) microspheres 
can target macrophages and regulate macrophage activities.  
The specific aims of this thesis are listed below: 
1. Fabricate an implantable drug delivery device capable of long-term pulsatile and 
continuous drug release, characterize the device materials and structure, achieve a 
controlled drug release profile in vitro and evaluate the biological function of the released 
molecules both in vitro and in vivo. Specifically, we focus on developing a PTH pulsatile 
delivery device, which could achieve daily pulse release for 21 days and a PTH continuous 
delivery device, which could release drug in a linear manner for 21 days. 
2. Repurpose PTH in a local bone defect model and evaluate the local PTH release effects 
on bone repair. Specifically, we develop a 3D nanofibrous (NF) scaffold and PTH release 
devices and combine the two components so that the device delivers PTH locally into the 
scaffold. The biological function of distinct PTH release kinetics in bone regeneration will 
be examined and evaluated to determine the optimal release pattern in terms of osteogenic 
outcome. The optimal delivery system will then be compared with the standard PTH 
injection.  
 5 
3. Develop BAM microspheres to target macrophages and manipulate macrophage 
function. Specifically, we develop a novel bioconjugation strategy to conjugate “eat me 
signal” lipid molecules onto the microspheres surface. The biological function of the BAM 
microsphere and the interaction between the BAM microspheres and the macrophages will 
be evaluated both in vitro and in vivo. 
The chapter arrangements of this thesis are listed below: 
Chapter 2 provides a general literature review of the current biomimetic drug delivery in 
bone tissue regeneration from two aspects: (1) general considerations in delivery systems 
and (2) specific delivery strategies for various types of bioactive signal molecules.  
Chapter 3 begins the research part of this thesis with the fabrication of a long-term PTH 
delivery device. We synthesize surface erosion polymers, investigate their chemical and 
physical properties, and develop advanced technologies to fabricate drug delivery devices, 
which are capable of long-term pulsatile and continuous drug release respectively. A series 
of technologies have been developed to tune the properties of the delivery systems as so to 
achieve optimal release kinetics.  
Chapter 4 details the biological function of distinct PTH release kinetics in terms of the 
therapeutic effects on bone. PTH delivery devices were evaluated in a subcutaneous 
implantation model. With the capacity of the developed methodology and temporal 
controlled drug release, pulsatile and continuous PTH delivery devices were compared in 
terms of their potential to strengthen bone systemically. Long-term PTH pulsatile release 
was shown to be advantageous relative to continuous release. These results are published 
in Advanced Healthcare Materials[31].  
 6 
Chapter 5 builds a bone defect model to exploit the therapeutic potential of PTH in healing 
local bone defect. A platform, which combines the biomimetic 3D NF scaffold and the 
PTH delivery device, has been established to enable PTH local delivery. For the first time 
we have repurposed PTH in a local repair scenario. These results are published in 
Biomaterials[39]. 
Chapter 6 develops a bioconjugation strategy to fabricate biodegradable microsphere to 
mimic apoptotic cells. Controlled surface conjugation and presentation of the “eat me 
signal” lipid molecule was achieved and the biomimetic BAM microspheres have 
demonstrated to target macrophages and manipulate the macrophage activity. Biomimetic 
NF scaffold loaded with BAM microspheres resulted in a drastic increase in endogenous 
mesenchymal stem/progenitor cell recruitment into the scaffold when compared with 
control microspheres. By targeting macrophage phagocytosis, the BAM/scaffold construct 
resulted in critical-sized bone defect repair. 
The final chapter, chapter 7, summarizes the thesis work with major conclusions and 
discusses some possible future directions related to this dissertation. 
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CHAPTER 2 
Drug Delivery Strategies in Bone Tissue Engineering 
 
2.1 Introduction 
A variety of signaling molecules have been identified and demonstrated to play a crucial 
role in regulating the cellular activity and microenvironment in bone tissue development 
and regeneration. The bioactive signal molecules are not only limited to growth factors, 
they also include small molecules[40, 41], peptides/proteins[42, 43], hormones[44], 
antibodies[45, 46], and nuclei acids[47, 48], which have been investigated for their ability 
to induce and accelerate bone regeneration (Figure 2.1.1). Different types of signal 
molecules contribute to the bone regeneration process using different mechanisms and 
therefore require specific delivery methods and kinetics. This chapter will review the types 
and mechanisms of the various bioactive signal molecules and the general considerations 
in drug delivery system (DDS) design. We will also discuss using the examples of recent 
research progress. 
 8 
 
Figure 2.1.1 Bone tissue engineering involves cells, scaffold and signal molecules. Signal molecules can be incorporated 
into the scaffold to recapitulate the microenvironment and stimulate bone healing. While growth factors have been widely 
used, other types of signal molecules are under intense investigation to exploit their potential in promoting bone 
regeneration. 
2.2 Bioactive Signal Molecules 
Various biological signal molecules play important roles in regulating cellular activities 
and tissue development[49]. Traditionally the term “growth factor” refers to proteins or 
polypeptides capable of promoting tissue growth[50], but it does not accurately reflect 
other types and functions of bioactive signal molecules in certain situations. Besides the 
typical protein or polypeptide-based growth factors, many other types of signal molecules 
such as hormones and nucleic acids have also demonstrated great potential in promoting 
bone tissue regeneration. Each category of molecules possesses unique physiochemical 
properties and biological mechanisms, which require specific delivery system design 
strategies. 
Growth factors 
 9 
In this chapter the term “growth factor” refers to soluble, secreted signaling polypeptides 
or proteins, which can be synthesized by a wide variety of cells and play an important role 
in the regulation of cell proliferation, migration, differentiation and ECM synthesis[51]. 
Growth factors usually exhibit short-range diffusion through the ECM and act locally[52]. 
A multitude of growth factors are involved in regulating the bone regeneration process and 
some of these growth factors (such as bone morphogenetic protein-2 (BMP-2)[53, 54], 
BMP-7[43, 55, 56], vascular endothelial growth factor (VEGF)[57, 58] and fibroblast 
growth factors-2 (FGF-2)[59, 60]) have demonstrated great potential in numerous 
preclinical studies. Unfortunately, the promising results seen in animal models have yet to 
be translated successfully to human trials, mainly due to concerns over their side effects 
and safety. VEGF for example, has a strong tendency to induce vascular permeability, 
which may lead to systemic hypotension and edema[61, 62]. Most of the complications 
concerning BMPs are related to heterotopic bone formation[63] and BMP-2 is also known 
to increase risk of cancer development[64]. The majority of growth factors that are 
currently used in clinical settings are delivered at a high enough dose to ensure the local 
concentration reaches therapeutic levels. Negative side effects associated with growth 
factors derive from poorly controlled drug release and supra-physiological level dosage. 
Therefore, there is a strong need to develop a delivery system for growth factors that 
allows the effective low dose to be delivered through precisely controlled release kinetics 
and tight localization in vivo. 
Endocrine secretion molecules (e.g. hormones) are a class of signaling molecules which 
are produced by glands in multicellular organisms and then transported by the circulatory 
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system to target distant organs to regulate physiology, including tissue growth, function, 
and development[65]. To reach their potential in promoting tissue regeneration, these 
molecules need to be delivered at specific time points and follow a certain pattern[66, 67]. 
For example, parathyroid hormone (PTH) is a hormone that is crucial to regulating bone 
remodeling, where bone tissue is alternately resorbed and rebuilt over time[68]. When 
given exogenously, pulsatile PTH administration promotes bone formation, whereas 
continuous PTH exposure results in bone resorption[29]. Currently, PTH is the only FDA 
approved anabolic (i.e. bone building) agent for the osteoporosis treatment in the US[30, 
69] and its anabolic action has also been demonstrated to improve osseous healing[70, 71]. 
Although PTH has great potential as a regenerative agent to improve bone formation, its 
current administration via systemic injection is not suitable for localized defect 
regeneration. An engineered pulsatile system capable of delivering PTH to the local site to 
preserve its bioactivity and to induce the optimal anabolic action is highly desired[32]. 
Nucleic acids 
Nucleic acids alter cellular function and modulate the tissue regeneration process at the 
genetic level. DNAs and mRNA encoding for growth and differential factors can enable 
protein expression for an extended period of time[72]. For example, genes encoding for 
BMPs[73, 74], FGF-2[75], insulin-like growth factors (IGFs)[76], TGF-β[77], platelet-
derived growth factor (PDGF)[78], and VEGF[79] have been shown to induce bone 
regeneration. In addition, the use of non-coding genes such as siRNA[80, 81] and 
miRNA[47], which regulate gene expression and cell activity, have recently emerged as 
novel therapeutic agents and also demonstrated great potential in bone repair. Owing to 
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electrostatic repulsion, negatively charged nucleic acids (DNAs and RNAs) cannot easily 
cross the negatively charged cell membrane[82]. The rapid degradation of some RNAs in 
vivo presents another challenge[83]. For these reasons, gene vectors are usually used to 
protect and deliver genes in vivo. Viral and non-viral vectors have been used to deliver 
genes into the desired cells and each different vector has its advantages and 
disadvantages[84, 85], which will be discussed in detail in the next section.  
Other bioactive agents 
A series of antibiotics and anti-inflammatory drugs have been also considered in 
combination with scaffolds[86] for tissue engineering including bone repair[40]. The aim 
is to reduce the bacteria or inflammation in a wound to a level at which wound-healing 
processes can take place. It has been shown that sustained antibiotic release was effective 
in controlling infection at the bone defect caused by debridement, and supported bone 
tissue healing[87]. 
Minerals such as calcium-phosphonate (CaP) and hydroxyapatite have been widely used in 
a variety of orthopedic implants and scaffolds[88-90], and these minerals and the ions 
released have been demonstrated to promote pre-osteoblast proliferation and 
differentiation[91]. Uniform and controlled deposition of minerals throughout the implants 
can be achieved through various methods. Simulated body fluid (SBF) incubation was 
originally developed to achieve mineral deposition onto scaffolds but this process was 
time-consuming, taking several weeks to form ideal mineral deposition[92]. Subsequently, 
mineral electrodeposition has been developed and was able to rapidly generate mineralized 
CaP coating on the scaffold surface. This approach offers significant advantages over 
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conventional SBF mineralization in that a high quality mineral coating can be achieved 
within a short time (0.5-3 hours typically) and the surface topography of the deposits can 
be tailored by controlling the electrochemical process parameters[93]. 
2.3 General Considerations in Delivery System 
Although different types of signaling molecules require specific delivery mechanisms, 
there are important universal considerations and factors in the design of delivery platforms. 
Specific strategies and examples will be discussed in the next section. 
Spatial controlled release within the tissue 
The concentration and spatial distribution of signal molecules play a key role in tissue 
regeneration and development[94]. The population of nearby cells sense the concentration 
gradient of signal molecules and responds in a concentration-dependent way[95]. The drug 
concentration and spatial distribution near the delivery vehicle is the major determinant of 
the drug efficacy and effects. For example, numerous studies have shown that there is a 
threshold dose of BMP for in vivo bone induction and the amount of bone formation is 
largely dependent on the BMP dose used. In a rat femur segmental defect model, 1.4 µg of 
BMP2 did not result in union, whereas a dose of 11µg was sufficient for complete 
union[96]. Therefore, it is crucial to deliver an effective amount of drug to the defect site. 
In general, the local drug concentration and spatial distribution is determined by both tissue 
physiology (i.e. drug diffusion rate and elimination rate) and properties of the delivery 
system properties (drug release rate and dosing).  
Insufficient control over the spatial distribution of the drug can lead to potential side 
effects and toxicity in non-target tissues. For example, the most recognized side effect 
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related to BMP-2 use is ectopic bone formation, most likely due to BMP-2 leakage outside 
of the implant site[97]. After spinal fusion surgery, ectopic bone formation occurs in the 
patients who were administrated BMP-2 at a rate of nearly 6 times (70.1%) more than the 
control patients who were not administrated BMP-2 (12.9%)[98].  
Biomimetic temporal controlled release 
The bone healing process involves multiple phases: the initial inflammatory phase, soft 
callus formation, mineralization, and bone remodeling. Multiple factors are involved in the 
different phases in certain time-dependent or temporal patterns[99].  Biomimetic drug 
delivery strategies have been exploited to simultaneously or sequentially deliver multiple 
signals to mimic the natural healing process to enhance therapeutic effects synergistically 
and optimize the osteogenic outcome[27, 49]. It is known that natural osteogenesis is 
preceded by angiogenesis in the bone repair process. A combination of angiogenic (such as 
VEGF), cell recruiting (such as PDGF) and osteogenic (such as BMPs) growth factors has 
been designed and demonstrated a synergistic effect that is more beneficial to bone repair 
than any one growth factor delivered alone[100, 101].  
Temporally controlled release is also critical for some drugs (e.g. endocrine secretion) that 
need to be delivered at specific time points and follow a certain pattern of distribution to be 
effective. Even given the same dose of a drug, distinct release patterns often lead to 
dramatic differences in the therapeutic outcome[31]. Therefore, precise control over the 
temporal distribution of the drug is essential to achieving the desired therapeutic effect[39]. 
Biocompatibility and safety issue 
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Biocompatibility and safety are required for DDSs and tissue engineering applications. 
Many different materials can be used to fabricate the delivery vehicles, including synthetic 
polymers, natural polymers and inorganic materials[102]. The materials and their 
degradation products must be safe and biocompatible to not cause excessive immune 
responses[103]. Typical synthetic polymers include poly(α-hydroxyester)s, 
polyanhydrides, polyorthoesters, poly(ethylene glycolide) (PEG), and poly(vinyl alcohol) 
(PVA)[103, 104]. The most commonly used poly(α-hydroxyester)s are homo- and 
copolymers of lactide and glycolide, because of their wide range of biodegradability and 
well-accepted biocompatibility[105]. Some natural polymers such as fibrin, collagen, 
chitosan, alginate, and hyaluronic acid have also been widely used as these materials have 
an innate capacity to interact with cells and undergo cell-mediated degradation[106]. 
Silica-based inorganic materials have been investigated as drug carriers in preclinical 
studies and while they show low cytotoxicity, most of them are non-degradable in the 
human body[107, 108]. 
Additionally some responsive drug delivery systems require external stimuli such as 
pH[109, 110], temperature[111, 112], light[113, 114], ultrasound[115, 116], electrical[117] 
and magnetic fields[118]. The safety issues associated with application of these stimuli 
also require careful investigations. Safe and less-invasive stimuli are more likely to 
translate into clinical applications. 
2.4 Biomimetic Strategies in Drug Delivery 
The importance and complexities of bioactive signal molecules in regulating cellular 
activities and bone healing suggests that sophisticated DDSs mimicking the natural healing 
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process are critical to achieve optimal therapeutic effects and thereby the desired bone 
regeneration outcome. Various methods and strategies have been exploited to enable 
spatiotemporal control over the drug release kinetics (Figure 2.4.1). 
 
Figure 2.4.1 Various drug delivery strategies for signal molecules. Different types of signal molecules require specific 
delivery system to achieve the optimal therapeutic effects.  Delivery systems, which have been developed and are 
currently used and/or are under investigation for bone tissue engineering applications, include surface presentation, 
controlled sustained release, preprogrammed release, responsive release and gene transfection. Copyright © 2016 by 
Nature Publishing Group, reprinted with permission of Nature Publishing Group, from Zhang et al 
Surface presentation 
Various techniques have been explored to present drug molecules on the surface of the 
scaffold, so that they are available for contact with cells migrating into the scaffold, acting 
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as localized biological cues to regulate cell behavior[119]. Surface presentation enables 
site-specific drug delivery and could reduce potential off-target side effects of the drugs. 
Physical adsorption and chemical conjugation are the two main methods for presenting 
drug molecules on the scaffold surface.  
Physical adsorption usually relies on an interaction between the scaffold surface and the 
drug molecules, such as electrostatic interactions, hydrogen bonding, and hydrophobic 
interactions[120, 121]. The scaffold surface can be further modified to improve its affinity 
for drug molecules[122]. For example, heparin has often been used to modify the scaffold 
surface chemically or physically to improve binding of the growth factors to the scaffold. 
There are many studies that report the controlled release of BMPs, PDGF, VEGF and other 
growth factors in a heparin-modified scaffold[123-127]. While there are certain preferred 
features, the passive adsorption approach could be of limited control over drug retention 
and result in burst release or diminished bioactivity in some cases[119]. Physiological 
conditions such as temperature, acidity and mechanical movement could also interfere with 
the physical interactions, affecting the effectiveness of surface presentation.  
Chemical conjugation, or covalent bonding, offers prolonged and more stable drug 
molecule presentation than the physical adsorption method. For this process, scaffold 
surface needs to be activated with functional groups, which can then conjugate with drug 
molecules through proper chemical reactions[128]. However, in many cases, commonly 
used polymeric materials for bone tissue engineering are biodegradable polyesters, which 
lack reactive functional groups. In these instances, there are various methods to activate the 
scaffold surface via post modification (such as plasma treatment, chemical etching, surface 
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coating) but it should be noted that the activation treatment conditions need to be properly 
adjusted to maintain scaffold integrity[129, 130]. Another approach involves 
functionalizing the matrix materials or blending functional molecules with the main matrix 
materials prior to the scaffold fabrication. A primary concern is that the conjugation 
reaction may lead to a change in the conformation of the drug molecule, especially for 
biologics and result in loss of the bioactivity. Therefore many drugs are pre-modified (e.g. 
conjugating to a PEG spacer)[131, 132] or drug mimics (growth factor peptide 
mimics)[133] are utilized. Various bioconjugation reactions have been investigated and the 
reactions conducted in aqueous solution or under mild reaction conditions are particularly 
favorable. Amidation, esterification and click reactions are among the most commonly 
used reactions[134]. For example, BMP2 mimicking peptide, P24, has been conjugated 
onto acrylic groups-bearing PLLA nanofibrous (NF) scaffold via the thiol-ene click 
reaction[135]. The scaffold decorated with BMP-mimicking peptide was able to retain its 
bioactivity and induce significant osteogenic differentiation of rabbit bone marrow-derived 
mesenchymal stem cells (BMSCs) compared to a non-modified scaffold, inducing ectopic 
bone formation in nude mice[133].  
Controlled sustained release 
Controlled sustained release of drug molecules is the prominent drug delivery strategy in 
bone tissue engineering and aims to provide the desired drug concentration at the local 
regeneration site. Physical encapsulation of the drugs into polymeric materials is the most 
commonly used method and the release kinetics can be controlled by the matrix 
degradation and drug diffusion rate[136].  The drugs can be either encapsulated inside the 
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scaffold matrix[137] or in separate delivery vehicle such as micro/nanoparticles[138], 
liposomes[139].  
Direct loading of the drugs into the scaffold matrix is the simplest way to achieve sustained 
drug release and many techniques have been developed including solvent casting, in situ 
polymerization, phase separation, electrospinning, gas foaming and more[140-142]. The 
major challenge with this strategy is to protect the bioactivity of the drugs from the harsh 
scaffold fabrication process. Most growth factors and other type biologics cannot be 
dispersed directly in polymer solution as the solvent can temper their bioactivity. Another 
drawback of this strategy is the lack of control over the release kinetics. For example, 
growth factors have been electrospun into NF scaffolds but they usually aggregate on the 
outer surface, resulting in the burst release[119].  
Encapsulating the drugs in separate delivery vehicles instead of directly within the scaffold 
matrix is a promising alternative strategy. Micro/nanospheres have long been used for drug 
encapsulation and various methods have been investigated to retain the drug bioactivity 
and achieve controlled release kinetics[43]. Additionally, a solvent annealing technique has 
been developed to immobilize the drug-loaded microspheres on the scaffold surface[143]. 
This method enables single or multiple drugs to be released in a spatially and temporally 
controlled fashion throughout the scaffold and also enables the drug release profiles to be 
individually designed without altering the scaffold structure. BMP7-loaded microspheres 
have been immobilized onto cell-free NF scaffolds, which were tested in subcutaneous 
implantation in rats[43]. BMP-7 was released from the scaffold-bound microspheres in a 
controlled fashion with high bioactivity and induced bone formation within the scaffold.  
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In contrast, the scaffolds with BMP-7 adsorbed were unable to induce osteogenesis, owing 
to the loss of bioactivity and short release duration of the BMP-7. In another study, such 
BMP-loaded microspheres mixed with an injectable scaffold and stem cells of apical 
papilla induced ectopic mineralized dentin formation[144].  
Drug molecules can also be incorporated into liposomes, however, they are relatively 
unstable in a physiological environment, which results in short release duration[145, 146]. 
Sustained drug release can also be achieved using porous inorganic materials but safety 
and degradation issues limit their translational potential into clinical applications[147]. 
Preprogrammed release 
While sustained delivery is a simple form of preprogrammed delivery, more sophisticated 
preprogrammed delivery systems are designed to utilize the spatiotemporal sensitivity of a 
patient to drugs to achieved optimal therapeutic effects[148, 149]. A common approach to 
achieve preprogrammed drug delivery involves multi-compartment constructs where drugs 
are pre-loaded in different compartments that have different release kinetics[42, 150]. 
Bulk- and surface-eroding polymers have been used as matrix materials for the 
compartments and can be engineered to achieve the desired release kinetics. Another 
strategy takes advantage of the development of nano/microfabrication techniques and 
functional materials to make drug delivery chips and responsive vehicles and the drug 
release can be either programmed in the chip or triggered by remote stimuli[151]. 
Preprogrammed DDSs are used to facilitate sequential release of multiple drugs to enhance 
bone regeneration. Instead of delivering single molecule at high doses, the safety and 
efficiency of the delivery system can be improved by delivering multiple signal molecules 
 20 
at relatively low doses in a sequential manner. DDSs loaded with multiple osteogenic and 
/or angiogenic factors have shown improved osteogenic outcomes[55, 150, 152, 153].   
For some drugs, different release patterns for the same drug can lead to distinct therapeutic 
outcomes, so achieving the specific drug release pattern is essential to achieve the desired 
therapeutic effects. As previously discussed, the anabolic or catabolic action of PTH highly 
depends on its delivery pattern. Pulsatile PTH administration improves bone 
microarchitecture, mineral density, and strength, whereas continuous exposure of PTH 
leads to bone resorption. A pulsatile delivery device has been developed and achieved PTH 
pulsatile delivery for 4 d but this its limited time frame, the device was not evaluated for its 
therapeutic function[154]. An electronic microchip based PTH delivery device has been 
fabricated and tested for long-term remote controlled PTH pulsatile release[151].  
Although the microchip device demonstrated controlled pulsatile delivery, explanation 
surgery is needed after the drug release is complete and the fabrication costs and safety 
issue are also of great concern. A biodegradable pulsatile delivery device that degrades and 
is absorbed in vivo without the need to be surgically removed is highly desirable.  
Responsive release  
Responsive delivery systems that release drugs in response to local physiological signals or 
external stimuli have received increasing attention[155]. Such on-demand drug release 
could likely reduce side effects caused by excess drug dosing found in conventional 
administration[155, 156]. Commonly used stimuli include pH, temperature, electric or 
magnetic field, ultrasound, light irradiation and biomolecules. These responsive systems 
involve “smart” responsive materials, so that the materials undergo considerable changes 
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in response to the stimuli and thereby change the drug release kinetics (e.g. release rate, 
dosing and duration).  
Responsive delivery systems have been used in systemic treatments, including most 
commonly cancer therapy[156, 157] but with limited success in tissue engineering 
applications. The regeneration process often requires long-term drug release, while most of 
the responsive systems suffer from the short release duration and irreversible responsive 
release[158]. Additionally, the biocompatibility and biodegradability of the functional 
materials and the safety concerns associated with the external stimuli limit their application 
in tissue engineering. 
One promising class of responsive delivery systems for tissue engineering is the 
biomolecule-sensitive system[159].  This kind of bio-inspired system is triggered by the 
local environment and would not need external stimuli. A protease cleavage-based 
triggering mechanism has been developed to initiate local drug release. A 
metalloproteinase (MMP) is a protease that is upregulated in angiogenesis and cell 
invasion. A MMP-cleavable crosslinker has been incorporated into a PEG-based hydrogel 
for local rhBMP-2 delivery to the site of bone defects[160]. Prior to MMP exposure, BMP-
2 remained as a precipitate within the PEG matrix and was not released over a period up to 
5 d. After implantation in the bone defect, cells migrate and invade the hydrogel matrix 
resulting in MMP secretion and the degradation of the MMP-sensitive PEG network. This 
causes BMP-2 dissolution and release, leading to efficient bone regeneration. Similarly, 
cell-mediated release of VEGF has demonstrated local and controlled induction of 
angiogenesis[161].  
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Gene transfection 
The goal of gene therapy is to deliver genes to the bone defect areas so they can regulate 
the expression of biomolecules (such as proteins) and cell activity to enhance proliferation 
and/or osteogenic differentiation. Gene transfection is often mediated by either a viral 
vector[85] (such as retrovirus, adenovirus, adeno-associated virus, herpesvirus) or a non-
viral vector[162, 163] (such as polycations or liposomes). Viral vectors have shown high 
gene transfection efficiency, however, associated safety issues, immune response, and side 
effects are of serious concern and greatly limit the translation of this approach into clinical 
use. The main advantage of non-viral vectors over viral vectors is their superior safety with 
additional benefits including ease of fabrication and scale up. Liposome-based transfection 
vectors including Lipofectamine (a commercial non-viral vector) have been explored to 
transport genes into cells in vitro but most liposomes exhibit low stability in the 
physiological environment[164] . Polymeric non-viral vectors, including polyethylenimine 
(PEI), chitosan and other polycation-based vectors often suffer from low efficiency and 
considerable cytotoxicity[165, 166]. Moreover, both viral and non-viral transfection 
systems only allow for one-time or short-term delivery, whereas sustained release is 
typically required for bone regeneration. For this reason, there have been a limited number 
of gene therapies capable of in vivo bone regeneration reported[167]. 
New approaches are being actively pursued to overcome current limitations in gene 
delivery for bone tissue engineering. Recently a water-soluble hyperbranched polymeric 
vector was developed that can incorporate the desired genes when it assembles into a stable 
nanoshell structure[47]. This unique vector-gene complex, or polyplex, provides excellent 
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stability that polyplexes remained intact even after harsh sonication.  Polyplexes loaded 
with miRNA-26a have been encapsulated in biodegradable polymer microspheres[47] to 
achieve long-term controlled miRNA-26a release. This delivery system enabled two-stage 
control over the gene release: sustained release of the polyplexes from the microspheres 
and efficient gene transfection into cells by the polyplexes. Microspheres loaded with the 
polyplexes were immobilized within the scaffold to provide spatially controlled 
distribution to prevent undesired off-target side effects. This study showed that the 
delivered miRNA-26a targets Gsk-3β to increase osteoblast activity, resulting in the 
regeneration of critical-sized calvarial bone defects in both healthy and osteoporotic mice. 
2.5 Conclusions 
Significant progress has been made both in the understanding of the molecular mechanisms 
in tissue development and regeneration and in the design of biomimetic biomaterials. 
Various biomimetic DDSs have been developed to mimic the natural healing process and 
provide spatiotemporally controlled drug release. The integration of DDSs with bone 
implants or scaffolds could lead to advanced tissue engineering therapy for bone defect 
repair. Biomimetic DDS can also serve as a novel platform to study the basic biology of 
how signal molecules manipulate cell activity and tissue development. 
A variety of biological and engineering challenges remain to be addressed in the future. 
Further qualitative and quantitative understanding of the complex interaction and 
cooperative signaling between the signal molecules, microenvironment and physiology 
could provide guidance to achieve precise spatiotemporal control and prediction of drug 
release and distribution. Development of more sophisticated delivery systems should rely 
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on multidisciplinary approaches that are based on biological principles and combine 
nanotechnology, advanced fabrication, and functional materials to deliver the required 
signals to the desired cells at the right time. Further research is needed to develop and 
optimize delivery systems for translation to clinical practice.  
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CHAPTER 3 
Preprogrammed PTH Delivery Device 
 
3.1 Introduction 
PTH is currently the only FDA-approved anabolic agent for the treatment of osteoporosis 
in the US[69], however its anabolic or catabolic action depends on the pattern of PTH 
delivery. Intermittent (pulsatile) administration improves bone microarchitecture, mineral 
density, and strength, whereas continuous exposure of PTH leads to bone resorption[29, 
68]. Current intermittent PTH treatment requires daily subcutaneous injection, which is 
neither a convenient nor a favorable choice of patients[154]. Thus, there is a clear clinical 
need for a patient-friendly alternative treatment capable of pulsatile PTH delivery, which 
would improve patients’ compliance and thereby their therapeutic outcome.  
A variety of delivery strategies have been explored to achieve controlled release in a 
pulsatile manner from various platforms such as micelles[168, 169], liposomes[170, 171], 
micro/nanoparticles[172, 173], hydrogel[174, 175], and microchips[176]. Based on the 
triggering mechanisms, these pulsatile delivery systems can be classified into stimuli-
responsive pulsatile release systems and self-regulated pulsatile release systems. In stimuli-
responsive systems, drug carriers release the loaded drug when triggered by external 
stimuli[177, 178] such as temperature[111, 112], pH[109, 110], light[113, 114], 
enzyme[179, 180], ultrasound[181, 182], biomolecules[183], and electric[117] or magnetic 
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fields[118]. These responsive systems can achieve pulsatile release but have also shown 
various limitations, such as an initial burst release, an irreversible triggered release, a short 
time interval (seconds to minutes), or a short release duration. Moreover, critical 
considerations have to be employed regarding the safety and biocompatibility of these 
responsive systems because many of the stimuli cannot be easily and safely utilized in 
patients and most of them are constructed with nondegradable polymers or inorganic 
materials[184]. Due to these limitations, few of them have been successfully implemented 
in patient care as a pulsatile PTH treatment. In self-regulated release systems, drugs are 
loaded in reservoirs sealed by a barrier material, which is usually composed of an erodible 
or biodegradable polymer[138, 154]. After the barrier material is eroded or degraded, drugs 
are rapidly released from the inner reservoir. The control over the pulsatile kinetics 
depends on the properties of the barrier materials and the design of the reservoir structure.  
In addition to the pulsatile releasing feature, the ability of long-term release is also 
critically important in developing a PTH delivery system. A series of studies indicate the 
beneficial effects of intermittent PTH administration on bone[185, 186], and its prominent 
anabolic action during three weeks of exogenous administration in an in vivo 
osteoregeneration mouse model[187]. Six-week systemic PTH administration was further 
demonstrated to be beneficial to osseous regeneration in a clinical human study[71]. 
Therefore, a delivery system capable of long-term release is needed to cover the effective 
therapeutic window. Previously, we developed a self-regulated pulsatile delivery device 
and achieved daily release of bioactive PTH for 4 d[154]. However, due to its limited time 
frame, the device was not evaluated for its therapeutic function. The challenge lies in the 
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structural design and fabrication techniques to enable a large number of controlled release 
pulses over a long duration. Ultimately, a biodegradable device that degrades and is 
absorbed in vivo without the need to be surgically removed is desirable.  
Herein, the aim of this work was to develop an advanced patient-friendly delivery system, 
which would overcome the hindrances of the current treatment regimen (daily injection) 
and achieve the optimal anabolic effect with preprogrammed PTH delivery. We designed 
implantable and biodegradable polymeric devices using a surface erosion polyanhydride 
(PA) developed in our lab[188] and advanced fabrication techniques to achieve 
preprogrammed daily pulses for 21 d. We also developed a device, which achieved 
continuous PTH release over 21 d. Henceforth, the devices served as a platform that 
allowed us to study the distinct PTH delivery patterns (pulsatile vs continuous) and their 
therapeutic effects on bone. 
3.2 Pulsatile Delivery Device Fabrication 
We fabricated a multipulse PTH delivery device consisting of alternating drug layers and 
isolation layers via an electrostatic-assisted layer-by-layer stacking technique. The 
isolation layer was made of biocompatible PA, which is bio- degradable through surface 
erosion. Bovine serum albumin (BSA) (control protein) or PTH was mixed with alginate to 
form the drug layer. Alginate was used as the carrier because of its biocompatibility and 
processability. We first investigated the surface potential of the two layers using Kelvin 
probe force microscopy (KPFM)[189, 190]. A PA or alginate-PTH layer was coated onto a 
gold substrate. The relative surface potentials of the two polymeric layers were calculated 
using the gold surface as reference (0 mV) (Figure 2.2.1 A).  
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Figure 2.2.1 Surface characterization of the PA films and drug films: Schematic illustration of the KPFM used to 
measure the surface potential of the films (A); Surface potential map and the potential difference between gold substracte 
and a PA film (B) or alginate-PTH film (C).  
We found that the PA layer was positive and the drug layer was nearly neutral. The surface 
potential of the PA layer (+40 mV) was about six times higher than that of the drug layer 
(+7 mV) (Figure 2.2.1 B and C). The intrinsic surface potential difference facilitated the 
generation of opposite electrostatic charges on the two layers. We generated positive 
charges on the PA layer by rubbing it with a Teflon film that has a strong tendency to gain 
electrons. Conversely, we generated negative charges on the drug layer by rubbing it with a 
glass slide that has a strong tendency to lose electrons (Figure 2.2.2 A). 
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Figure 2.2.2 The illustration of the rubbing, stacking, and sealing process to fabricate the pulsatile release device. A) The 
fabrication process of a multi- pulse delivery device via electrostatic-assisted layer-by-layer stacking technique. B) The 
electrostatic potential of the different layers after the rubbing process. C) A cross-sectional SEM micrograph of the 
multilayer pulsatile release device. 
The electrostatic voltages between the two different layers were measured with an 
electrostatic meter and the results indicated that we were able to generate opposite charges 
on the PA layer (+160 mV) and the drug layer (–80 mV) (Figure 2.2.2 B). One positive PA 
layer and one negative drug layer were attracted to each other and formed a bilayer 
structure. The bilayers were then stacked into a 21-bilayer structure. This technique 
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enabled close contact between drug layers and isolation layers and eliminated air gaps 
(Figure 2.2.2 C). Constructively, the drug layers were designed to be smaller than the 
isolation layers in diameter, preventing possible contact between adjacent drug layers, 
which could lead to leakage of drug between layers. The side and the bottom of the device 
were sealed with polycaprolactone (PCL), a slow biodegrading polymer[191], thus 
allowing unidirectional drug release from the top only.  
3.3 Pulsatile Device Characterizations and Release Kinetics 
The pulsatile release profile was preprogrammed by modulating the chemical composition 
and physical thickness of the isolation PA layer. The poly(SA-CPP) (sebacic acid (SA) and 
1,3-bis (p-carboxyphenoxy) propane (CPP)) has been used as components of FDA-
approved medical devices in human clinical application[192]. However, due to the 
hydrophobicity of the poly(SA-CPP), the hydrolytic degradation usually takes too long for 
an ideal pulsatile release profile. Therefore, we incorporated polyethylene glycol (PEG) 
segments into the poly(SA- CPP) and prepared a three-component PA (poly(SA-CPP-
PEG)) by condensation polymerization as described previously[188]. Nuclear magnetic 
resonance (NMR) spectroscopy confirmed the successful synthesis as the spectrum showed 
a set of typical poly(SA-CPP-PEG) peaks (Figure 2.3.1). 
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Figure 2.3.1 1H NMR (400 MHz, CDCl3) spectrum of an poly(SA-CPP-PEG). 
Scanning electron microscopy (SEM) was used to examine the PA degradation. The cross 
section of the uneroded polymer was uniform, while there were evident pores in eroded 
portions of the treated samples (Figure 2.3.2). The erosion front moving with time was an 
indication of surface erosion. The PA containing more PEG segments exhibited a faster 
erosion rate than those containing fewer PEG segments. It was also observed that the 
eroded surface roughness increased with increasing PEG content of the PA. The new PEG-
containing PA retained the surface erosion properties of the poly(SA-CPP) while imparting 
a large range of tunable erosion rate. 
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Figure 2.3.2 Degradation behavior of PA films. SEM micrographs of untreated PA stored under vacuum (A) and PA 
specimens with different compositions after erosion in 0.1M PBS at 37°C for 12 h: (B) SA/CPP/PEG=80/20/0, (C) 
SA/CPP/PEG=80/20/2, (D) SA/CPP/PEG=80/20/10.  
The “dissolution time” of the surface erosion polymer layer is proportional to the thickness 
of the layer. Therefore, the thickness of each isolation layer can be adjusted to achieve 
desired time intervals between adjacent pulses of drug release. PA isolation layers of 
varying thickness (50, 100, and 200 µm) were used to assemble the multilayer devices, all 
of which were able to deliver 21 pulses of protein but with different durations (Figure 
2.3.3). The average interval time be- tween two adjacent PTH peaks exhibited a linear 
relationship with the thickness of isolation layer and the linear regression equation is 𝑇(ℎ𝑜𝑢𝑟) = 0.26ℎ(µ𝑚)+ 7.5 (Figure 2.3.3 D).  
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Figure 2.3.3 In vitro pulsatile drug release profiles. BSA release from devices of various isolation layer thickness. A) 50; 
B) 100; C) 200 µm. D) The average time interval between adjacent pulses exhibited linear relation with the thickness of 
isolation layer. E) Bioactive PTH released in vitro from a pulsatile drug delivery device with 50 µm thick isolation layers.  
As also demonstrated, the degradation rate of the three- component PA escalated with 
increasing PEG content. Varying the chemical composition and the layer thickness allowed 
us to preprogram the release kinetics to target the entire three-week therapeutic window. 
The device made of 50 µm PA (weight ratio: SA-CPP-PEG = 80-20-2) could release 1 
pulse per day and was therefore chosen for PTH–PTH loading. Release kinetics of 
bioactive PTH was determined using an adenylyl cyclase stimulation and cAMP-binding 
assay[193], which showed that 21 pulses of bioactive PTH were achieved over three 
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weeks, and that released PTH retained around 80% bioactivity (Figure 2.3.3 E)  
3.4 Continuous Delivery Device Fabrication and Release Kinetics 
Another device, with identical shape, size, and component materials to those of the 
pulsatile release device, was engineered to deliver the same total amount of PTH but in a 
continuous manner. This continuous device was designed to serve as a control device in 
order to determine the in vivo therapeutic effect in response to different PTH delivery 
patterns. We employed a double emulsion method to prepare drug-encapsulated PA 
microspheres, which were then compressed into a disk of the same shape and size as the 
pulsatile device (Figure 2.4.1 A).  
 
Figure 2.4.1 Continuous release device fabrication and release profiles. A) Schematic illustration of the fabrication 
process of the PA microspheres via double emulsion method and the construction of the continuous delivery device. B) In 
vitro release of BSA from continuous drug delivery device with different PAs. C) In vitro bioactive PTH released from 
continuous drug delivery device with PA (80/20/2).  
We achieved linear continuous release of the model protein (BSA) (Figure 2.4.1 B). 
Interestingly, unlike most microsphere-based continuous delivery systems (such as 
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poly(lactic-co-glycolic acid), poly(lactic acid)[194, 195], there was no burst release and the 
sustained release of BSA from the new continuous release device was linear with release 
time. SEM observation showed that the uneroded PA particles were spherical in shape with 
smooth surfaces, and that during degradation in phosphate buffered saline (PBS), the size 
of the particles decreased, the particles lost the spherical shape, and fused together (Figure 
2.4.2).  
 
Figure 2.4.2 Degradation behavior of PA microspheres. SEM micrographs of untreated PA micrspheres stored under 
vacuum (A) and PA microspheres with different compositions after erosion in 0.1M PBS at 37°C for 12 h: (B) 
SA/CPP/PEG=80/20/0; (C) SA/CPP/PEG=80/20/2; (D) SA/CPP/PEG=80/20/10.  
Instead of being porous throughout the particles, which would likely lead to a burst drug 
release, the surface erosion property of the PA resulted in the degradation only on the 
surface, thus enabling the steady linear drug release from the microspheres. In addition, the 
 36 
unidirectional device design also contributed to the linear delivery kinetics, since the PBS 
only eroded spheres on the exposed disk surface and penetrated in a downward direction as 
the downmoving surface degraded.  
The release kinetics of the linear release device could also be modulated by varying the 
chemical composition of the PA. The drug release profiles showed that the drug release 
rate increased with increasing hydrophilic PEG segments (Figure 2.4.1 B). The device 
made of the highest PEG content (10%) PA released 100% of the drug in 400 h, whereas 
the device made of no PEG content PA only released 50% of the drug in 400 h. The PA 
(80-20-2) device was able to release 90% of the drug in 21 d, which was the targeted three-
week window of anabolic PTH treatment. Therefore, PTH was encapsulated into PA (80-
20-2) microspheres and bioactive PTH was measured using the adenylyl cyclase 
stimulation and cAMP-binding assay. The bioactive PTH was released from the device 
following a linear release profile with bioactivity not statistically different from that of 
released PTH from the pulsatile device (Figure 2.4.1 C).  
 
Figure 2.4.3 In vitro bioactive PTH release curves from the two different delivery devices. cAMP-binding assays were 
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used to determine the bioactive PTH amounts released from a pulsatile device (upper panel) and a continuous device 
(lower panel) at 3 time points: (A) day 1, (B) day 10, and (C) day 20 (n 1⁄4 3).  
In addition, the released PTH from both types of devices was collected every hour on days 
1, 10 and 20. The bioactivity of the released PTH was determined using the adenylyl 
cyclase stimulation and cAMP-binding assay. The released bioactive PTH data showed 
that pulsatile PTH release devolved from a sharp peak (day 1) to a relatively broader peak 
(day 20) over time (Figure 2.4.3 upper panel). This may be due to the increased diffusion 
distance of PTH through the residual PA layers. However, the pulsatile release feature was 
maintained over the 21 days. The bioactive PTH was released at a steady rate from the 
continuous device, which is consistent with the linear release behavior shown from the 
ELISA data (Figure 2.4.3 lower panel).  
Both types of devices were constructed with the same components: the drug (PTH), 
isolation or encapsulation materials (PA), and sealant material (PCL) but the distribution of 
PTH in the devices was different, resulting in distinct release profiles. In the pulsatile 
device, PTH was isolated by PA in a layer-by- layer structure, whereas PTH was confined 
in microdomains that were uniformly distributed throughout the continuous device. The 
surface erosion property of the PA (SA-CPP-PEG) is essential to achieve the two types of 
the release kinetics. In the pulsatile device, it enabled the daily-pulsed release because the 
PBS could only erode one isolation layer before releasing one drug layer. In the continuous 
device, the surface erosion property enabled the PTH release from microspheres on the 
exterior surface then gradually from those inside the device, resulting in the linear 
continuous drug release. Moreover, the structural tunability of this three-component PA 
enabled a broad range of interval time in the pulsatile device or release duration time in the 
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continuous device.  
3.4 Conclusion 
Implantable and biodegradable long-term pulsatile and continuous PTH delivery devices 
were designed to investigate the effects of PTH delivery patterns on systemic bone therapy. 
The advanced materials and fabrication techniques developed in this work enable us to 
deliver daily pulses of bioactive PTH from a pulsatile device and to deliver bioactive PTH 
in a linear manner from a continuous device for three weeks. Beyond the PTH delivery 
application, we expect the platform (continuous and pulsatile devices) to be useful in 
fundamental and translational studies on how temporal effects and release patterns of 
biomolecules regulate cell fate, tissue development, and regeneration.  
3.5 Experiment Section 
Fabrication of the Pulsatile PTH Delivery Device 
Three-component PAs composed of SA, CPP, and poly(ethylene glycol) (PEG, Mw = 
1000) were synthesized as previously reported. 1H NMR (400MHz, CDCl3) confirmed the 
synthesis of the PA: PEG (3.4–3.8 ppm), CPP (6.9 and 8.0 ppm), and SA (1.4–2.2 ppm). 
The PA was melted and compressed into layers of various thicknesses with error ≤10 µm. 
The PA layers were punched into disks of desired size (3 mm in diameter) as isolation 
films. BSA or PTH (1-34) (Bachem Bioscience Inc., Torrance, CA) was mixed with 
alginate in a 1:1.67 weight ratio. The mixture was dissolved in distilled water and the 
solution was cast into a film and freeze-dried for 1 d. The films were then punched into 
disks (2 mm in diameter). The PA films were rubbed with a Teflon film to generate 
positive surface charge and the alginate-PTH films were rubbed with a glass slide to 
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generate negative surface charge. One piece of the PA film and one piece of drug film 
attracted each other to form one bilayer. The 21 bilayers were stacked and then sealed 
using a 35% w/v PCL/dichloromethane (DCM) solution, leaving the top unsealed thus 
allowing one-direction erosion (from top to bottom). The device was vacuum dried for 3 d. 
Film Surface Characterization 
10% w/v PA/DCM solution or alginate-PTH aqueous solution was spin coated onto the 
gold substrate. KPFM (Bruker NanoMan atomic-force microscopy (AFM)) equipped with 
a conductive tip was used to map the surface potential in tapping mode and the data were 
analyzed with software (Nanoscope) equipped with the AFM. The drug layer was rubbed 
with a glass side and the PA was rubbed with a Teflon layer. The electrostatic voltages of 
the layers (Teflon, glass side, PA layer, and drug layer) were measured using a noncontact 
static meter (Electro-Tech Systems Static Meter Model 200).  
Fabrication of Continuous PTH Delivery Device 
To fabricate the continuous PTH release device, we employed the double emulsion method 
to prepare drug-encapsulated PA microspheres, which were then compressed into disks. 
Briefly, BSA (control protein) or PTH was dissolved in distilled water with 0.1% w/v 
gelatin. The drug solution was emulsified in a 10% w/v PA DCM solution, using a probe 
sonicator at an output power of 10 W (Virsonic 100, Cardiner, NY) for 10 s over an ice 
bath to first form a water-in-oil (w/o) emulsion. The w/o emulsion was then gradually 
added into 20 mL aqueous polyvinyl alcohol solution (1% w/v) under sonication at an 
output power of 20 W to form a water- in-oil-in-water (w/o/w) double emulsion. The 
solution was stirred at room temperature for 3 h to evaporate DCM and then centrifuged to 
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collect solid microspheres. The resultant microspheres were washed with distilled water 
three times and freeze dried. The microspheres were then compressed into disks and the 
bottoms and sides of the disks were sealed with a 35% w/v PCL/DCM solution, leaving 
only the top unsealed. The device was dried under vacuum for 3 d.  
In vitro Drug Release and PTH Bioactivity 
The protein-loaded devices were immersed in 1 mL PBS (0.1 m, pH = 7.4) and incubated 
at 37 °C. After designated times, the medium was collected and replaced with equal 
amount of fresh PBS. The collected medium was stored at −80 °C until analysis. The 
amount of released BSA was measured using a MicroBCA protein assay (Pierce, 
Rockford, IL). In vitro bioactivity of released PTH was determined using the adenylate 
cyclase stimulation assay and cAMP-binding protein assay. Briefly, human fetal 
osteoblasts were treated with PTH of known concentrations or with eluent from the PTH 
delivery devices for designated times in calcium- free and magnesium-free hanks’ balanced 
salt solution containing 0.1% BSA and 1 × 10−3 m isobutylmethylxanthine. After 
incubation of the treated cells at 37 °C for 10 min, the cAMP in the cells was extracted 
with ice-cold perchloric acid. The cAMP extracts were then neutralized by adding KOH 
and centrifuged to remove the precipitates. (3H)-cAMP was incubated with standards or 
unknowns and cAMP-binding protein for 90 min on ice. The unbound (3H)-cAMP was 
removed by adding dextran-coated charcoal. The samples were then centrifuged and the 
supernatant of each tube was decanted to a scintillation tube. The radioactivity of the 
supernatants was determined using a liquid scintillation counter and cAMP levels were 
calculated using the standard curve.   
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CHAPTER 4 
PTH Delivery Device in Systemic Delivery Application 
 
4.1 Introduction 
Current PTH administration relies on injection, but comparing different PTH release 
kinetics from a controlled delivery system has not yet been studied. PTH has been shown 
to promote bone formation in vivo via a net anabolic action, however it inhibits osteoblast 
differentiation and mineralization in vitro, indicating that the in vivo environment cannot 
be replicated using the in vitro model[196, 197]. Hence, in vivo models are a necessity to 
determine PTH’s optimal delivery mode from the engineered devices in terms of anabolic 
action. In this chapter, we investigate the engineered PTH release from both pulsatile and 
continuous release devices in vivo and study their systemic therapeutic effects on bone in a 
mouse model (Figure 3.1.1).   
 42 
 
Figure 3.1.1 Experimental design used to investigate the therapeutic effects of PTH released from the pulsatile delivery 
device and the continuous delivery device. The PTH delivery devices were subcutaneously implanted in mice and bones 
and serum were collected three weeks later to examine the systemic effects of the two PTH release modes on bone.  
4.2 PTH Delivery Device to Strengthen Bone 
With the PTH release devices fabricated and function confirmed, the PTH devices were 
evaluated in vivo to compare the pulsatile and continuous release modes in terms of 
anabolic effects on bone. Both pulsatile and continuous devices (4 mm in diameter and 
around 1.6 mm in thickness) were loaded with equal amounts of PTH and implanted 
subcutaneously in mice. Three weeks later, the tibia, vertebrae, and blood serum were 
collected and analyzed.  
MicroCT (µCT) evaluation showed that PTH released from the devices had obvious effects 
on the tibiae. The 3D reconstruction (Figure 3.2.1 A) and the quantitative analysis (Figure 
3.2.1 B and C) showed that the pulsatile PTH release significantly increased trabecular 
bone volume and cortical bone thickness, while the continuous PTH release acted in the 
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opposite way and decreased both trabecular bone volume and cortical bone thickness.  
  
Figure 3.2.1 The mouse tibia bone analysis after PTH release using the pulsatile and continuous releasing devices, 
respectively. A) Representative µCT reconstruction of trabecular bone (top) and cortical bone (below) of the mouse tibias 
from different treatment groups. B) Trabecular bone volumes. C) Cortical bone thickness. n = 5–7 per group, *P < 0.05, 
**P < 0.005, ***P < 0.001, #P < 0.05, ##P < 0.005, ###P < 0.001.  
Vertebral bone turnover and the osteoclastic response were examined using hematoxylin 
and eosin (H&E) staining and tartrate-resistant acid phosphatase (TRAP) staining (Figure 
3.2.2 A). Quantitative analysis of the bone area ratio showed that pulsatile PTH 
significantly increased bone area, while continuous PTH significantly decreased bone area 
compared to controls (Figure 3.2.2 B). The serum bone formation marker (pro-collagen I 
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intact N-terminal propeptide (PINP)) level was measured using an enzyme-linked 
immunosorbent assay (ELISA) and showed that the PINP levels were significantly 
elevated in the pulsatile PTH group (Figure 3.2.2 C).  
Interestingly, TRAP staining of the vertebrae showed that both PTH pulsatile and 
continuous delivery led to an increased number of TRAP-positive osteoclasts (OSCs) per 
bone perimeter (Figure 3.2.2 D and E), but the serum bone resorption marker TRAP 5b 
level was signi cantly higher only for continuous PTH release (Figure 3.2.2 F).  
 
Figure 3.2.2 Mouse vertebral bone response to pulsatile and continuous PTH releases. A) Representative H&E staining 
of vertebrae of different PTH delivery groups. B) Vertebral bone area/tissue area analyzed by histomorphometry. C) 
Serum PINP level measured by PINP ELISA. D) Representative TRAP staining of vertebrae of different PTH delivery 
groups. E) Osteoclast (OSC) numbers per bone perimeter. F) Serum TRAP5b level measured by ELISA; pulsatile groups: 
n = 9–12 per group, continuous groups: n = 6–9 per group, *P < 0.05, **P < 0.005, ***P < 0.001, #P < 0.05, ##P < 
0.005, ###P < 0.001. Scale bar: 0.5 mm (A) and (D).  
These in vivo results indicated that while delivering the same amount of PTH, the pulsatile 
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release device enhanced bone growth through increasing bone remodeling evidenced by an 
increase in bone formation marker PINP and enhanced osteoclast numbers, while 
continuous release induced bone resorption through enhanced osteoclast activity. The 
systemic pulsatile PTH release was found to be superior in terms of anabolic action in bone 
and significantly increase bone volume systemically after three weeks, so such delivery 
method could potentially reduce the treatment duration from two years to a significantly 
short duration.  
4.3 Biocompatibility and Biodegradability of the Devices 
It has always been a critical concern in implantable products whether degradation 
byproducts (such as monomers, acids) of a biodegradable polymer result in toxicity and 
negative effects. The components (SA-CPP and PEG) of PA used in this study have been 
used as components of FDA-approved medical devices in the human body. The 
degradation products of the PA copolymer are similar to those of the two components, 
which potentially have similar biocompatibility.  
To help determine biocompatibility, we examined the pH value change during the 
degradation of the PA devices in vitro and the body response to the implants in vivo. The 
pH value of the PBS medium, in which devices were immersed, remained about 6.8, close 
to neutral pH 7, over time as the devices degraded. There was no significant difference 
between pulsatile and continuous devices (Figure 3.3.1 A) since the same amounts of PA 
were used to fabricate the two types of devices. The in vivo body response to the devices 
was evaluated using histological analysis of the devices explanted three weeks after 
subcutaneous implantation. Most parts of the devices had been degraded, leaving the slow 
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degrading sealant shell of PCL (Figure 3.3.1 B), which would degrade eventually as 
reported earlier. H&E staining was performed to assess inflammation at the implant sites in 
vivo (Figure 3.3.1 C and E). The devices were mainly surrounded by granulation tissue 
composed mostly of macrophages and lymphocytes and partial encapsulation by a 
fibrovascular connective tissue wall was noted. The inflammatory infiltrate was localized 
to the area surrounding the devices with limited extension into the adjacent adipose tissue. 
Overall, all the materials (alginate, PA, and PCL) used to construct the delivery devices are 
biocompatible and biodegradable. Subcutaneous implanted devices degraded in vivo and 
resulted in an encapsulation of the materials with minimal acute inflammation.  
 
Figure 3.3.1 The degradation of pulsatile and continuous release devices in vitro and in vivo. (A) Change of solution pH 
value over time (drug delivery devices were immersed in 1 ml 0.1M PBS at 37°C). N=3 (B) Drug delivery devices before 
implantation and after 3-week implantation. H&E staining of pulsatile device at low (C), and high (D) magnification. 
H&E staining of continuous release device at low (E) and high (F) magnification. Scale bar: 1mm (C and E) and 50 µm 
(D and F).  
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4.4 Conclusion 
Implantable and biodegradable long-term pulsatile and continuous PTH delivery devices 
were designed to investigate the effects of PTH delivery patterns on systemic bone therapy. 
The pulsatile device was preprogrammed to deliver daily pulses of bioactive PTH and the 
continuous device to deliver bioactive PTH in a linear manner for three weeks. We 
demonstrated that systemic pulsatile PTH release was able to increase bone via enhancing 
bone remodeling, whereas the continuous PTH release resulted in bone resorption via 
elevated osteoclast resorption activity. The biodegradable pulsatile PTH delivery device 
has the potential to be a patient-friendly PTH therapy, which could be administered only 
once (implantation) instead of daily injection. In addition, the device is biodegradable and 
resorbable in vivo, eliminating the need of removal surgery. Beyond the PTH delivery 
application, we expect the platform (continuous and pulsatile devices) to be useful in 
fundamental and translational studies on how temporal effects and release patterns of 
biomolecules regulate cell fate, tissue development, and regeneration.  
4.5 Experiment Section 
Subcutaneous Implantation  
All animal procedures were carried out under the guidelines of and were approved by the 
Institutional Animal Care and Use Committee of the University of Michigan. Pulsatile or 
continuous PTH delivery devices were implanted into subcutaneous pockets created from a 
midline incision on the backs of C57B6 mice (The Jackson Laboratory, Bar Harbor, ME) 
at postnatal d 10. Three weeks after implantation, the mice were euthanized and whole 
blood was obtained by intracardiac blood draw, serum separated and kept frozen until 
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biochemical assays were performed.  
 Micro CT analysis  
3D analyses of mice tibiae were performed using µCT as previously described[198]. 
Briefly, formalin fixed tibiae were embedded in 1% agarose and placed in a 19 mm 
diameter tube and scanned over their entire length using a µCT system (µCT100 Scanco 
Medical, Bassersdorf, Switzerland). Scan settings were 12 µm voxel size, medium 
resolution, 70 kVp, 114 µA, 0.5 mm AL filter, and an integration time of 500 ms. 
Trabecular bone parameters were measured over 50 slices using an 180 mg cm−3 
hydroxyapatite (HA) threshold beginning 15 slices distal to the growth plate; cortical bone 
parameters were measured over 30 slices beginning 250 slices proximal to the tibia–fibular 
joint using a 280 mg cm−3 HA threshold. The trabecular bone volume and cortical bone 
thickness (Ct.Th) were quantified using the manufacturer’s evaluation software (Scanco 
µCT 100).  
Bone histological and histomorphometric analysis  
The Mice vertebrae samples were fixed with 4% formalin, decalcified with 10% EDTA for 
2 weeks and subsequently embedded in paraffin. Hematoxylin & eosin (H&E) and 
Trichrome staining of the coronal sections (5 mm thick) were performed by the histology 
core at the University of Michigan School of Dentistry. Tartrate-resistant acid phosphatase 
(TRAP) staining was performed using the Leukocyte Acid Phosphatase Assay (Sigma) 
following the manufacturer's protocol. Bone static histomorphometric analyses for bone 
area and osteoclast number were performed using a computer-assisted histomorphometric 
analyzing system (Image-Pro Plus version 4.0; Media Cybernetics, Inc., Silver Spring, 
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MD).  
Serum biomarker analysis  
The whole blood was obtained by intracardiac blood draw. After centrifugation for 10 min 
at 13000 rpm, serum was separated and kept frozen until biochemical assays were per- 
formed. Serum procollagen I N-terminal propeptide (P1NP) (MyBioSource, Inc) and 
TRAP5b (Novatein Biosciences, MA) ELISA immunoassays were performed following 
the manufacturer's protocols.  
Statistical analysis  
All numerical data are presented as mean ± SD. All P values were two-tailed and P < 0.05 
was considered statistically significant. One-way ANOVA test was applied to compare 
different groups using GraphPad InStat software (GraphPad).  
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CHAPTER 5 
PTH Delivery Device in Local Delivery Application 
 
5.1 Introduction 
In the previous chapter, we demonstrated systemic PTH delivery from the delivery device 
and the pulsatile delivery could promote bone formation systemically. However, extending 
PTH utilization from systemic treatment to localized application for bone defect 
regeneration has not been achieved. The major drawbacks of repurposing PTH as a 
therapeutic for local defect repair include its systemic side effects and its administration via 
daily injection, which is inconvenient for patient compliance. Many different drug delivery 
strategies have been investigated but most of them center on systemic administration[32]. 
Successful systems to deliver PTH to the local site, to preserve PTH bioactivity and to 
induce the optimal anabolic action are lacking.  
In this work, we developed a novel acellular biomaterial strategy to promote bone 
regeneration by incorporating local PTH delivery in a 3D biomimetic scaffold (Fig. 1). 
Biodegradable drug delivery devices were designed to preprogram the delivery of PTH in 
either a pulsatile or continuous manner for 21 days using the surface erosion PA. We 
investigated the effects of the two distinct kinetics, pulsatile and continuous, in a local 
calvarial defect regeneration model. This platform allowed us to explore the potential of 
PTH for the treatment of localized bone defects (Figure 4.1.1).  
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Figure 4.1.1 Experimental design of using a 3D cell-free scaffold and a PTH deliver device (pulsatile or continuous) to 
repair calvarial bone defect in a mouse model.  
5.2 PTH Delivery Device to Repair a Bone Defect 
First of all, 3D scaffolds were prepared, which plays an important role in defining the 3D 
micro- environment for regenerative cells. Pore size, porosity and surface architecture are 
important parameters to design an ideal scaffold for regeneration[14]. In this work, we 
combined the sugar spheres leaching technique with the thermal induced phase separation 
technique to fabricate NF PLLA scaffolds with inter-connected spherical pore network 
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(Figure 4.2.1 A and B). The spherical pores of the scaffold ranged from 250 mm to 420 
mm and the porosity was as high as 98.5%. The major organic component of bone is 
collagen, which self-assembles into nanofibers ranging from 50 to 400 nm in 
diameter[199] and the PLLA scaffold surface (inset in Figure 4.2.1 B) had the similar NF 
feature of collagen.  
 
Figure 4.2.1 Scanning electron microscopy (SEM) images of scaffold and PTH delivery devices. (A, B) NF PLLA 
scaffold with interconnected spherical pore network; (C, D) the pulsatile PTH release device; and (E, F) the continuous 
PTH release device. Scale bars: 400 mm in A, C, E and 50 mm in B, D, F. Inset in B shows the NF architecture of the 
scaffold at a higher magnification (scale bar: 2 mm).  
To determine the optimal PTH release mode to ensure desired PTH anabolic action in bone 
regeneration, the pulsatile device (21 layers) and the continuous device (21 days) were 
compared in identical experimental set ups to access the outcomes of bone regeneration in 
a round defect (2.3 mm in diameter) created in the mouse skull (Figure 2.1 C and E). BSA 
loaded pulsatile devices were used as vehicle controls. In the positive control group, we 
injected PTH for 3 weeks using a standard systemic administration dose (40 mg/ kg/d), 
which showed notable anabolic effects as reported before. Both the pulsatile devices and 
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continuous devices were loaded with the same amount of PTH as the total standard 
injection amount.  
Eight weeks after implantation, µCT reconstruction of the skulls (Figure 4.2.2 A) showed 
that local pulsatile PTH release resulted in the best regeneration outcome among all 
groups; whereas continuous PTH release resulted in less bone compared to the BSA 
control group. 
  
Figure 4.2.2 µCT characterization of the local defect repair in 8 weeks. (A) Representative µCT reconstructions of 
mouse calvarial defects in different PTH delivery groups. (B) The new bone volume; and (C) The new bone mineral 
density. n =6-9 per group, *P < 0.05, **P < 0.005, #P < 0.05, ##P < 0.005, ###P < 0.001.  
H&E (Figure 4.2.3 A) and Trichrome staining (Figure 4.2.3 B) showed that in the pulsatile 
PTH group, collagen-rich bone tissue (stained pink in H&E staining and dark blue in 
Trichrome staining) was formed throughout the scaffold, whereas only fibrous tissue was 
present in the continuous PTH group. Areas and volumes of newly formed bone were 
quantitatively analyzed using µCT and histomorphometry, revealing that the PTH injection 
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significantly promoted bone growth in the NF scaffold compared to the control BSA 
group. Further, local pulsatile PTH release significantly increased bone volume and 
connected bone tissue regeneration even compared to systemic PTH injection (Figures. 
4.2.2 and 4.2.3).  
 
Figure 4.2.3 Histological characterization of the bone defect repair 8 weeks after implantation. (A) H&E staining, (B) 
Trichrome staining, and (C) TRAP staining of different PTH delivery groups. Scale bars: 0.5 mm in the left column and 
0.2 mm in the right column.  
TRAP staining (Figure 4.2.3 C) and the resultant osteoclast analysis (Figure 4.2.4 B and C) 
showed that both pulsatile and continuous PTH release devices increased the number of 
osteoclasts compared to BSA controls. Over 60% of the osteoclasts were aligned along the 
new bone tissue in the pulsatile PTH group, while most of the TRAP positive cells (over 
85%) in the continuous PTH group were found distributed throughout the fibrous tissue 
inside the scaffold. The osteoclast distribution in the local pulsatile and the systemic 
injection groups were similar, but local delivery recruited significantly more osteoclasts.  
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Figure 4.2.4 Quantitative analysis of the bone repair using histomorphometry. (A) Newly formed bone areas, (B) TRAP 
positive osteoclasts numbers, and (C) the distribution of the osteoclasts in the bone area and scaffold area quantified 
using histomorphometry. n=6-9 per group, *P < 0.05, **P < 0.005, #P < 0.05, ##P < 0.005, ###P < 0.001.  
Moreover, as the components of the devices were biodegradable and biocompatible 
polymers, the devices degraded/eroded over time and minimum immune reaction and 
inflammation were observed.  
5.3 Reduced Systemic Side Effects 
Mouse tibiae from the different groups were examined using µCT to assess the potential 
systemic side effects of the local PTH releases. As expected, 3 weeks of PTH injection 
significantly increased trabecular bone volumes[200]. PTH released from the local device, 
both pulsatile and continuous, however, did not affect the trabecular bone, such that the 
volume of the trabecular bone remained unchanged compared to the BSA control group 
(Figure 4.3.1 A and B). Serum was isolated at the end of the 3-week treatment regimen and 
ELISA analyses were employed to evaluate the levels of bone biomarkers. Serum P1NP 
(bone formation marker) and TRAP5b (bone resorption marker) suggested that the 
intermittent systemic injection of PTH increased systemic bone turnover, as the levels of 
P1NP and TRAP5b in the blood were significantly elevated compared to the local delivery 
groups (Figure 4.3.1 C and D).  
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Figure 4.3.1 Analysis of the systemic effects of PTH release from the local delivery devices. (A) Representative mCT 
reconstructions of the tibiae from different treatment groups; (B) Trabecular bone volume; (C) Serum P1NP level and (D) 
TRAP5b level measured using ELISA kits. n=6-9 per group, *P < 0.05, **P < 0.005, #P < 0.05, ##P < 0.005, ###P < 
0.001.  
5.4 Discussion 
PTH is the only FDA approved anabolic agent for the treatment of osteoporosis and its 
efficacy in stimulating bone remodeling, with net promotion of bone formation and few 
side effects, has been well established[29, 68, 201]. The unique anabolic action of PTH 
implies its potential in bone regeneration, yet studies have been lacking in this type of 
administration for local regenerative application[202, 203].  
In this chapter, we achieved bone defect repair using local pulsatile PTH delivery. The 
success of repurposing PTH from osteoporosis to bone regeneration was achieved by 
developing a novel long-term pulsatile PTH delivery device to accurately deliver PTH to 
the defect sites to induce local anabolic effects.  
Current PTH treatment which relies on systemic administration, was shown to be less 
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effective in enhancing local defect repair and to have unintended systemic side effects. 
Local treatment, in contrast, has advantages such as maintaining relatively higher local 
bioactive agent levels, reducing dose concentration or number of dosages, and 
circumventing possible adverse side effects resulting from systemic administration[119, 
204].  
The anabolic actions of PTH are also highly dependent on intermittent delivery and a 
specific temporal profile. Current treatment requires daily injections, which is cumbersome 
for both patients and physicians. A self-regulated pulsatile delivery system capable of long-
term delivery would be desirable. Although that various delivery strategies have been 
developed, none has achieved successful and patient-friendly pulsatile delivery. 
Electrically controlled drug release microchips were fabricated to realize controlled PTH 
daily pulse release but such a device would require secondary surgery for removal[184].  
In the present study, patient-friendly drug delivery devices were utilized to expand PTH 
application and to determine optimal PTH release kinetics, pulsatile or continuous, in a 
local bone regeneration model. The pulsatile delivery device, made of alternating PA 
isolation layers and PTH drug layers, was preprogrammed to deliver daily PTH pulses for 
21 days. The PTH/alginate blend was freeze-dried, cut into drug layers and then packed 
into the pulsatile device. This method enabled high drug loading efficiency and capacity 
and the bioactivity of the PTH was well preserved during the 3 weeks of PTH release. The 
continuous device, with identical shape and polymeric materials to that of pulsatile device, 
was loaded with the same amount of total PTH and delivered within the same time period 
(21 days). The difference between these two types of devices is the PTH distribution, 
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where PTH is distributed in a layered structure to achieve pulsatile release or PTH is more 
uniformly distributed in the matrix within microspheres to achieve continuous release.  
A highly porous NF scaffold was used to evaluate the two engineered PTH release modes 
for regeneration application. The PLLA scaffolds, with NF surface feature, were 
demonstrated to selectively enhance the adsorption of cell-adhesion proteins including 
fibronectin and vitronectin, increasing osteoblast adhesion[205]. Besides, such NF 
scaffolds enhance the osteoblastic differentiation of a variety of stem cells, including 
BMSCs, which are integral for bone defect healing[206, 207]. Here, the histological cross- 
section of the control group (scaffold with BSA delivery) also supported the conclusion 
that the NF structure alone could induce certain level of bone formation in vivo (Figure 
4.2.2). Furthermore, with different PTH release kinetics incorporated, distinct osteogenic 
outcomes in the NF scaffolds were observed. Local pulsatile PTH delivery significantly 
improved the defect repair, generating connected and robust new bone tissue throughout 
the scaffold, whereas local continuous delivery resulted in less bone in the NF scaffold 
versus the BSA control group.  
From the TRAP staining data (Figure 4.2.3 C), we noticed that both PTH releases, pulsatile 
and continuous, were able to increase osteoclast numbers. Pulsatile PTH release induced 
stronger bone remodeling with enhanced numbers of the osteoclasts aligned along the 
formed bone tissue, while continuous PTH release resulted in reduced bone, with increased 
osteoclasts, not lining the bone, but throughout the fibrous tissue inside the scaffold. The 
results indicate that the local pulsatile PTH release was able to induce beneficial catabolic 
actions by stimulating osteoclasts to realize the needed bone remodeling activity in this 
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specific bone-regeneration scenario.  
As has been shown 3 weeks systemic PTH injection is also able to increase bone turnover 
and generate notable anabolic effects. Thus, we also compared the local pulsatile PTH 
release device with the standard systemic PTH injection treatment, and found that local 
release was advantageous over the systemic injection in improving the defect repair. This 
local strategy may have benefitted from the more localized higher bioactive PTH level and 
the longer action time in the local defect sites. Given the 8 min half-life of PTH[208], only 
a part of the total bioactive PTH could reach the defect sites considering the bioactivity 
loss during circulation time when PTH is given systemically. On the contrary, the local 
delivery strategy is more likely to maintain bioactive PTH level within an effective range 
for the needed period of time.  
In addition to enhancing local defect repair, local PTH release led to little undesired 
systemic effects, whereas PTH systemic injection resulted in clear systemic effects as 
expected. µCT and serum data showed that PTH injection significantly increased tibiae 
trabecular bone volume and serum bone formation biomarkers, while PTH local release did 
not affect tibiae trabecular bone and exerted only minor effects on serum bone formation 
biomarkers. These results indicate that PTH release from the device was likely to be 
delivered and act more locally. 
The polymeric materials used in this system, PLLA, PA, PCL and alginate, have been used 
as components of FDA-approved devices for certain medical applications[209]. The 
biodegradable and biocompatible devices developed in this study elicited minimum 
immune response and inflammation, which are particularly advantageous for the defect 
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repair application. In addition, this approach needs only a one-time administration 
(implantation) instead of daily injection for 3 weeks and there is no need for retrieval of the 
empty devices after the drug release is complete. Therefore, the implantable device is more 
patient-friendly and is promising for clinical translation. 
5.5 Conclusion 
In summary, PTH, a FDA-approved anabolic agent for osteoporosis, was repurposed to 
repair local bone defects. Current PTH treatment requires daily injection, while in this 
work PTH was incorporated into a novel biodegradable device, which was capable of 
delivering PTH to the defect area in a preprogrammed pulsatile manner. It was found that 
local continuous PTH release inhibited, while local pulsatile PTH release promoted bone 
regeneration. In addition, the local pulsatile delivery strategy significantly improved the 
osteogenic outcome and reduced the systemic side effects compared to the standard PTH 
injection treatment. This acellular therapy provides a novel strategy to improve bone defect 
repair by integrating a biomimetic scaffold and an anabolic local delivery strategy to 
maximize the regenerative effects within the intended areas of interest. This biomaterial 
technology holds promise for bone defect regeneration without addition of external cells, 
the burden of daily PTH injections, or the need for device removal surgery. The technology 
could also be readily employed to deliver other therapeutics or their combinations in a 
tailored manner to maximize their therapeutic effects. 
5.6 Experiment Section 
Materials 
Three-component PA was synthesized by polymerizing sebacic acid (SA), 1,3-bis (p-
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carboxyphenoxy) propane (CPP), and poly(ethylene glycol) (PEG, MW=1000 Da) as 
previously reported. Poly(l-lactic acid) (PLLA, Resomer L207S) with an inherent viscosity 
of 0.8-1.2 dl/g (0.1% in chloroform, 25 oC) was purchased from Boehringer Ingelheim 
(Ingelheim, Germany). PTH (1-34), was obtained from Bachem Bioscience Inc (Torrance, 
CA). SA, CPP, PEG, polycaprolactone (PCL), polyvinyl alcohol (PVA), bovine serum 
albumin (BSA), alginate, gelatin, fructose, mineral oil, tetrahydrofuran (THF) and 
dichloromethane (DCM) were purchased from Sigma-Aldrich Company (USA) and used 
as received. Phosphate- Buffered Saline (PBS) was purchased from Life Technologies 
Company (USA). 
3D nanofiberous (NF) scaffold fabrication 
3D NF PLLA scaffolds with inter-connected spherical pores were fabricated as previously 
described[92]. Briefly, fructose sugar spheres were made by emulsion technique. 50 g 
fructose was melted at 130 oC into clear light yellowish liquid and the liquefied sugar was 
gradually added into 50 mL mineral oil with 1.5 mL Span 80 under vigorous stirring for 3 
min to create emulsion. The mixture was cooled down in an ice-bath to solidify the sugar 
spheres and sifted with standard sieves to separate them by size.  
Spheres of desired-size (250-420 mm) were collected, washed with hexane for three times, 
and added to a Teflon mold. The mold was heat-treated at 37 oC for 15 min to achieve the 
desired inter- connected pore structure. After bonding the sugar spheres, hexane was 
removed under vacuum. PLLA/THF (10% w/v solution) was then cast into the sugar 
sphere assembly and the whole construct was stored at 80 oC over night to induce phase 
separation. The phase- separated samples were immersed into distilled water to extract the 
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solvent and leach away the sugar spheres. Last, the polymer scaffolds were freeze-dried 
and punched into desired size (2.3 mm in diameter and 1.5 mm in thickness).  
Calvarial bone-defect repair model construction  
All animal procedures were performed following a protocol approved by the University of 
Michigan Institutional Animal Care and Use Committee. C57BL/6 mice were randomly 
divided into four groups. Animals were anaesthetized with isoflurane (2%) inhalation. A 
2.3 mm craniotomy defect centered on the parietal calvarial bone was created using a 
trephine. A blank scaffold was placed to fill in the defect and a delivery device (pulsatile 
PTH, continuous PTH or BSA control) was placed adjacent to the scaffold with the 
opening side facing the scaffold. The PTH injection group did not receive PTH delivery 
devices; instead subcutaneous injection of PTH (40 mg/kg/d) was administrated for 21 
days. The mice were euthanized 8 weeks after implantation. The skull and tibiae were 
harvested  
Micro CT analysis  
For the calvarial bone analysis, the skulls were scanned with a fixed global threshold of 
20%. 3D reconstruction of the skull and quantitative analyses were performed. A 2.3 mm-
round region of interest centered on the defect was determined and the bone volume (mm3) 
(BV) and bone mineral density (BMD) in the area were measured using manufacturer's 
software (Scanco µCT 100).  
For the tibiae analyses, tibiae were scanned over the entire length. A fixed global threshold 
of 18% (180 on a grayscale of 0-1000) was used to segment trabecular bone from non-bone 
areas. A region of 0.75 mm right below the growth plate was analyzed to quantify the 
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trabecular bone volume.  
Bone histological and histomorphometric analysis  
The calvarial samples were fixed with 4% formalin, decalcified with 10% EDTA for 2 
weeks and subsequently embedded in paraffin. Hematoxylin & eosin (H&E) staining of the 
coronal sections (5 mm thick) were performed by the histology core at the University of 
Michigan School of Dentistry. Tartrate-resistant acid phosphatase (TRAP) staining was 
performed using the Leukocyte Acid Phosphatase Assay (Sigma) following the 
manufacturer's protocol. Bone static histomorphometric analyses for bone area and 
osteoclast number were performed using a computer-assisted histomorphometric analyzing 
system (Image-Pro Plus version 4.0; Media Cybernetics, Inc., Silver Spring, MD).  
Serum biomarker analysis  
Three weeks after implantation, the mice were anaesthetized with inhalation of isoflurane 
(2%) and blood was collected by tail blood draw. After centrifugation for 10 min at 13000 
rpm, serum was separated and kept frozen until biochemical assays were per- formed. 
Serum procollagen I N-terminal propeptide (P1NP) (MyBioSource, Inc) and TRAP5b 
(Novatein Biosciences, MA) ELISA immunoassays were performed following the 
manufacturer's protocols.  
Statistical analysis  
All numerical data are presented as mean ± SD. All P values were two-tailed and P < 0.05 
was considered statistically significant. One-way ANOVA test was applied to compare 
different groups using GraphPad InStat software (GraphPad).  
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CHAPTER 6 
Biodegradable Apoptotic-Cell Mimicking Microspheres 
 
6.1 Introduction 
Macrophages are often associated with diseases and inflammatory immune responses[210] 
and have been generally considered negative for tissue homeostasis. However, recent 
studies have revealed diverse functions of macrophages, which are emerging as not only 
key players in the orchestration of inflammation resolution and tissue regeneration[211-
213], but also as crucial participants in maintaining tissue homeostasis[214, 215]. Pettit, et 
al. coined the term ‘osteomacs’ as macrophages which are located in close proximity to 
osteoblasts in vivo and support osteoblasts function[216]. Depletion of macrophages leads 
to a reduction in cortical and trabecular bone mass[217]. Macrophages are also critical to 
the fracture healing process. They are responsible for the clearance of damaged tissue and 
the initiation and progression of early endochondral ossification[215, 218]. The secretion 
of cytokines and growth factors stimulated by macrophage engulfment of apoptotic cells 
(termed efferocytosis) could regulate osteoblasts and mesenchymal stem cells and fuel the 
bone turnover and remodeling process. Indeed, following efferocytosis, the secretion of C-
C motif chemokine ligand 2 (CCL2), aka monocyte chemotactic protein 1 (MCP1), and 
transforming growth factor-ß 1(TGF-ß1) were increased[219]. Both have been known to 
enhance the recruitment of mesenchymal progenitor cells and play key roles in bone 
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repair[219-221]. These findings show that modulation of the macrophages efferocytosis 
process has great potential in therapeutic bone repair. The efferocytosis process is initiated 
and mediated by the macrophages’ recognition of the signal molecules released or 
presented by apoptotic cells.[222-224] One important category of signal molecules is 
termed the “eat me” signals, which are expressed on the surface of apoptotic cells[225, 
226].  
Phosphatidyserine (PS) lipid, a well-recognized “eat me” signal, has been incorporated into 
liposomes to regulate inflammation and promote tissue repair via systemic injection.[227] 
Herein, we hypothesize that biodegradable apoptotic-cell mimicking microspheres (BAM) 
could mimic the apoptotic cells, attract macrophages, initiate efferocyctosis and subsequent 
marrow stromal cells (MSCs) recruitment and benefit new bone regeneration. To test this 
hypothesis, we developed BAM, which are biodegradable polymeric microspheres (MS) 
with the PS lipid conjugated on their surface and then seeded these BAM onto a porous 
and nanofibrous (NF) tissue-engineering scaffold. We then examined the potential of BAM 
in enhancing bone regeneration in the 3D space defined by the scaffold in a calvarial bone 
defect model. 
6.2 BAM Microsphere Fabrication  
To immobilize PS lipids onto polymeric MS, we selected the avidin-biotin conjugation because of this 
strategy’s high efficiency and versatility[228]. We synthesized MS-biotin (Figure 6.2.1 A) and PS-biotin 
(Figure 6.2.2 A) respectively and used avidin to link MS-biotin and PS-biotin to yield BAM.  
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Figure 6.2.1 Synthesis of MS-biotin. (A) Synthesis route of MS-biotin. (B) FTIR spectrum of HEMA-PLLA MS before 
and after functionalization, showing the peaks corresponding to conjugated molecules (arrowed). (C) A schematic picture 
of the conjugation between MS-biotin and FITC-BSA-biotin via avidin. (D) Confocal images of FITC-BSA conjugated 
MS-biotin ( scale bar: 5µm). 
MS were made from biodegradable, biocompatible polyesters to ensure that they were safe 
in biological systems[31, 43]. However, a majority of polymers which belong to this 
category lack functional groups for conjugation reactions.[133] Therefore, we first initiated 
PLLA polymerization with HEMA to form HEMA-PLLA, and then used HEMA-PLLA to 
formulate MS of desired size (in the range of 1-5µm). Amine groups were modified onto 
the particle surface through click reaction between thiol groups of cysteine and alkene 
groups of HEMA-PLLA MS. The amine groups were then functionalized into biotin by 
reacting with NHS-biotin (Figure 6.2.1 A). FTIR spectrums confirmed the intended surface 
chemistry changes (Figure 6.2.1 B). To further demonstrate the success of biotin 
modification and visualize the conjugation sites, fluorescent moieties (FITC-BSA-biotin) 
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were conjugated to the prepared MS-biotin through avidin conjugation (Figure 6.2.1 C). 
Confocal imaging showed that fluorescent signal was emitted only from the surface of MS-
biotin (Figure 6.2.1. D). No fluorescent signal was detected from the unmodified MS. 
PS lipids, like most lipid molecules, are hydrophobic. An organic chloroform-methanol 
mixture was used as a solvent to dissolve the PS lipids. PS were modified with NH2-PEG-
NH2 through EDC/NHS mediated Steglich esterification in order to increase the PS 
hydrophilicity and then reacted with NHS-biotin to obtain PS-biotin. The PS-biotin 
chemical structure was confirmed using both FTIR (Figure 6.2.2 B) and NMR (Figure 
6.2.2 C). 
 
Figure 6.2.2 Synthesis of PS-biotin. (A) Synthesis route of PS-biotin. (B) FTIR spectrum of PS before and after 
functionalization, showing the peaks corresponding to biotin molecule (arrowed). (C) 1HNMR spectrum of the 
synthesized PS-PEG-biotin. 
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To prepare BAM via the avidin-biotin conjugation, we first added avidin to an aqueous 
MS-biotin suspension so that the avidin bound to MS-biotin to form MS-avidin, and then 
added PS-biotin into the MS-avidin to form MS-PS, henceforth termed BAM. 
Immunofluorescence staining visualized the successful conjugation of PS onto the MS. We 
labeled the MS with FITC (green fluorescence) in both control MS and BAM groups and 
incubate them with Annexin V-TRITC (red fluorescence)[229], an antibody that shows 
high affinity for PS lipids. We found that the red fluorescence was specifically bound to 
BAM but not to the control MS, indicating that PS presentation on the surface of the 
prepared BAM (Figure 6.2.3 A).  
The avidin-biotin interaction enables well-controlled and highly efficient conjugation 
under mild reaction conditions. We eluted the PS-biotin from the BAM and measured the 
amount of PS-biotin in the supernatant to determine the conjugation efficiency[230]. The 
results showed that as much as 85% PS-biotin was conjugated at various feeding amounts 
(Figure 6.2.3 B), indicating a high conjugation efficiency. 
 
Figure 6.2.3 Conjugation between MS-biotin and PS-biotin. (A) Confocal images of FITC-tagged control MS and BAM 
after incubation with Annexin V (a red fluorescence PS binding protein. Scale bar: 10 µm. (B) Amount of PS conjugated 
on the surface of BAM at different feeding amounts. N=3. 
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6.3 BAM Microspheres Enhanced Macrophage Phagocytosis in vitro 
Microspheres (BAM or control MS) were co-cultured with macrophages to study 
efferocytosis in vitro. TEM showed that both types of microspheres were engulfed by 
macrophages and that they kept their original spherical shape inside macrophages (Figure 
6.3.1). Qualitative confocal microscopy imaging revealed that macrophages engulfed more 
BAM than control MS (Figure 6.3.2 A, B & C). Quantitative FACS data confirmed that 
macrophages internalized significantly more BAM than control MS at 0.5 and 1 h in the 
co-culture. This indicates that the PS modification mimicked apoptotic cells and enhanced 
macrophage efferocytosis (Figure 6.3.2 D). 
 
Figure 6.3.1 TEM observation of the macrophages (A) and engulfment of control MS (B) and BAM (C) at low 
magnification (top panel) and high magnification (bottom panel). 
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Figure 6.3.2 Macrophage phagocytosis in vitro. Confocal images of macrophages alone (Deep red stained) (A), and 
FITC-tagged control MS (B) or BAM (C) engulfed by macrophages 1 h after incubation. Scale bar: 10 µm. (D) Flow 
cytometry analysis demonstrated that BAM were more efficiently internalized by F4/80 positive macrophages at 30 min 
and 60 min compared to control MS. N=4 per group, ***P<0.0005. 
To study the macrophages response after efferocytosis of BAM, macrophages were 
cultured alone or co-cultured with microspheres (BAM or control MS). Cells were 
harvested for gene expression analysis at multiple time points and supernatants were 
collected after 24 h for analysis of secreted proteins. Gene level expression results revealed 
that control MS and BAM had insignificant influence on BMP2, BMP7 and TGF-β1 gene 
expressions at both 6 h and 24 h time points (Figure 6.3.3 A, B & C). The osteogenic BMP 
genes (BMP2 & BMP7) were expressed at levels more than 2 orders of magnitude lower 
than those in BMSCs. Control MS significantly increased CCL2 gene expression at 6 h 
compared to macrophages alone group. BAM further increased CCL2 gene expression by 
20 times or higher than control MS for all time points (Figure 6.3.3 D). Consistent with the 
gene expression data, protein level analysis showed significantly increased CCL2 secretion 
in BAM-macrophage co-cultures. No significant protein secretion difference was observed 
between control MS-macrophage co-culture and macrophage alone groups (Figure 6.3.3 
E).  
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Figure 6.3.3 In vivo macrophage response to BAM. Phagocytosis of BAM did not modulate the BMP2 (A), BMP7 (B) 
and TGF-β1 (C) gene expression but significantly increased CCL2 production by macrophages at both gene expression 
(D) and protein (E) level. N=4, ##P<0.01, ####P<0.0001 for ANOVA test, and ***P<0.0005, ****P<0.0001 for post t-
test.  
6.4 BAM Microspheres Promoted Cell Migration 
A transwell assay was used to investigate the ability of the conditioned medium collected 
from the experimental culture groups to induce the migration of BMSCs (Figure 6.4.1 A). 
Conditioned medium collected from macrophages alone doubled BMSC migration 
compared to the control medium alone. Conditioned medium from the BAM-macrophage 
co-cultures resulted quadrupled BMSC migration compared to control medium (Figure 
6.4.1 B). Different concentrations of recombinant CCL2 were also examined to determine 
CCL2 effects on BMSC migration. Results showed that a concentration of 10 ng/ml CCL2 
increased BMSCs migration by about 70% when compared with control medium. 
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However, CCL2 concentration up to 100 ng/ml did not cause any further increase in 
BMSC migration. These results suggest that BAM stimulated macrophages to secrete 
cytokines, such as CCL2, which could contribute to the enhanced BMSCs migration. 
 
Figure 6.4.1 (A) Transwell migration assay of mouse BMSCs cultured for 8 hours in conditioned media from 
macrophages alone, co-culture of macrophages with control MS, and BAM. (B) Numbers of cells migrated were counted 
after fixation and hematoxylin staining. N=8, ####P<0.0001 for ANOVA test and ***P<0.0005 for post t-test. 
Control MS or BAM were immobilized onto NF PLLA scaffolds and implanted in mice 
subcutaneously to investigate the in vivo response to the different microspheres. The 
scaffold constructs were harvested at day 4 and day 7. Trichrome staining showed that 
higher numbers of cells were seen surrounding and infiltrating BAM-scaffold constructs 
compared to the control MS-scaffold constructs (Figure 6.4.2 A & B). F4/80 
immunohistological staining[214] also indicated that BAM (green) could recruit more 
F4/80 positive (red) macrophages than control MS into the scaffolds (Figure 6.4.2 C & D). 
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Figure 6.4.2 Scaffolds loaded with control MS and BAM 4 days and 7 days after subcutaneous implantation. Trichrome 
staining (A, B) and F4/80 immunohistological staining (C,D) of control MS (top panel) and BAM (bottom panel) scaffold 
at different time points. Particles were labeled with FITC green and F4/80 positive cells stained deep red. Scale bar: 
50µm. 
6.5 BAM Microspheres Promoted Bone Regeneration 
Cell-free scaffolds (alone, loaded with control MS or loaded with BAM) were used to fill 
critical-sized calvarial bone defects in C57BL/6 mice.   
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Figure 6.5.1 µCT and histological characterization of critical-sized defect repair after 8 weeks. Representative µCT 
reconstructions (A) and H&E staining (B) of mouse calvarial defects in scaffold groups. New bone volume (C) and new 
bone mineral density (D) was quantified by µCT and newly formed bone areas (E) were measured by histomorphometry. 
N =6 per group, ####P < 0.0001 for ANOVA test and ***P<0.005, ****P < 0.0001 for post t-test. 
Cell-free scaffolds (alone, loaded with control MS or BAM) were used to fill critical-sized 
calvarial bone defects in C57BL/6 mice. Eight weeks after implantation, similar amounts 
of bone formed in the plain scaffold and the control MS-scaffolds, indicating that the 
biomimetic NF scaffold could promote bone repair via enhanced osteoblasts differentiation 
and biomineralization, corroborated by our previous observation[231]. Control MS did not 
appreciably enhance the bone repair. Excitingly, the bone defect was completely filled in 
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the BAM-scaffold group (Figure 6.5.1). To better evaluate the bone repair process and 
investigate the reasons which lead to the osteogenic outcome differences between the 
control MS group and BAM group, a time course study was conducted to examine the 
implanted constructs (control MS-scaffold and BAM-scaffold) at different time points (3 
days, 1, 2, 4 and 8 weeks). NF scaffolds loaded with control MS were able to regenerate a 
very small amount of mineral tissue in 4 weeks, whereas a significant amount of mineral 
tissue started to form after 2 weeks implantation of BAM-scaffold (Figure 6.5.2) and 
substantial amount of bone was regenerated at 4 weeks and eventually the bone defect was 
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fully repaired at 8 weeks. 
 
Figure 6.5.2 µCT characterization of the critical-sized defect repair over time. (A) Representative µCT reconstructions of 
mouse calvarial defects at 1, 2, 4 & 8 weeks, (B) New bone volume, and (C) new bone mineral density were quantified. 
N =6 per group, *P < 0.05. 
F4/80 staining showed that the population of F4/80 positive macrophages remained at a 
stable and low level over 4 weeks within the control MS-scaffold. However, in BAM 
group, the population of F4/80 macrophages was significantly increased at day 3 post 
implantation and remained significantly higher than the level of MS-scaffold at day 7, but 
at the later time points the population was statistically indistinguishable from the MS-
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scaffold group (Figure 6.5.3 C & D). We also noticed that the macrophages were 
distributed throughout the scaffold at the early stage and then aligned along the scaffold 
and mineral tissue edges at the late stage, likely acting as the bone supporting 
macrophages. CCL2 expression was significantly increased at all time points within BAM-
scaffold, with the highest level expression exhibited at day 3 (Figure 6.5.3 E & F). 
Consistent with the in vitro transwell study, MSC population within the BAM-scaffold 
construct was higher than in the control MS-scaffold construct at all time points, especially 
at the early stage, evidenced by the increased double CD73+ & CD105+ expression (Figure 
6.5.3 I & J), which are two well-recognized MSC biomarkers. Following the early influx of 
MSCs, osteogensis was evaluated by monitoring osteocalcin (OCN) expression, an 
important late stage biomarker of osteogenesis[232, 233]. OCN expression was gradually 
and slightly elevated over time in the control MS group. OCN expression was significantly 
higher over time in the BAM group than in the MS group and increased with time (Figure 
6.5.3 G & H).  Taken together, BAM enhanced bone healing via promoted MSCs 
recruitment into the scaffold, initiated by the efferocytosis of BAM, which led to the 
increased macrophage population and CCL2 secretion. 
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Figure 6.5.3 Histological characterization and histomorphometric analysis of the defect area over time. Representative 
pictures of (A) H&E staining, scale bar 150µm, (C) F4/80 staining, scale bar 125µm,  (E) Immunofluorescence staining 
for CCL2 (red), DAPI staining for nuclei (blue), scale bar 100µm, (G) Immunofluorescence staining for OCN (red), 
DAPI staining for nuclei (blue), scale bar 100µm, (I) Immunofluorescence staining for CD73 (green), CD105 (red) DAPI 
staining for nuclei (blue), scale bar 200µm of mouse calvarial defects with either MS-scaffold or BAM-scaffold at 
different time points. Quantitative analysis of the defect area using histomorphometry. (B) Newly formed bone areas, (D) 
F4/80 positive cells numbers, (F) CCL2, (H) OCN expression and (J) double CD73+ and CD105+ expression in the defect 
areas. N=6~9 per group, *P < 0.05, **P < 0.01. 
To further confirm the essential role of CCL2 in the BAM mediated bone regeneration, we 
compared the BAM-scaffold construct in both WD and CCR2 (the CCL2 receptor) KO 
mice. Four weeks bone repair data showed that the bone regeneration was greatly impaired 
in the CCR2 KO mice, with limited response to BAM (Figure 6.5.4). Reduced F4/80 cells, 
MSCs and CCL2 expression were also observed compared to the WD mice group (Figure 
6.5.5). 
 
Figure 6.5.4 µCT characterization of the critical-sized defect repair in WT mice and CCR2 KO mice after 4 weeks. (A) 
Representative µCT reconstructions of mouse calvarial defects. (B) New bone volume, and (C) new bone mineral density 
were quantified. N =5 per group, *P < 0.05. 
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Figure 6.5.5 Representative pictures of (A) H&E staining, scale bar 150µm, (C) F4/80 staining, scale bar 125µm,  (E) 
Immunofluorescence staining for CCL2 (red), DAPI staining for nuclei (blue), scale bar 100µm, (G) 
Immunofluorescence staining for OCN (red), DAPI staining for nuclei (blue), scale bar 100µm, (I) Immunofluorescence 
staining for CD73 (green), CD105 (red) DAPI staining for nuclei (blue), scale bar 200µm of mouse calvarial defects with 
either MS-scaffold or BAM-scaffold. Quantitative analysis of the defect area using histomorphometry. (B) Newly formed 
bone areas, (D) F4/80 positive cells numbers, (F) CCL2, (H) OCN expression and (J) double CD73+ and CD105+ 
expression in the defect areas. N=6~9 per group*P < 0.05, **P < 0.01. 
6.6 Discussion  
Macrophages were originally known for their protective role in eliminating undesired 
pathogens, foreign bodies, and mediating inflammation and infection[234]. However, 
tissue resident macrophages have been found to hold a unique and vital role in maintaining 
tissue homeostasis and promoting tissue regeneration. Osteoclasts are classically 
considered resident macrophages in the bone tissue. They are known to play an important 
role in bone tissue homeostasis and repair, but recent studies suggest that non-osteoclast 
macrophages also play diverse and significant roles[216, 235]. 
Case in point, macrophages play an important role in bone fracture healing, which involves 
both the removal of damaged tissue and the initiation of prolonged regenerative response. 
It has been reported that while a certain number of osteoblasts matured into osteocytes, 
40% to 70% of osteoblasts underwent apoptosis and were subsequently cleared by 
macrophages[236]. Recent studies suggest that efferocytosis of these apoptotic osteoblasts 
could trigger the secretion of key factors that are capable of inducing an influx of stem 
and/or progenitor cells[219, 237]. Indeed, CCL2 and TGF-ß1 levels increased after the 
macrophage engulfment of apoptotic bone cells. These macrophages initiate a cascade of 
events that result in the recruitment of mesenchymal stromal cells via various growth 
 82 
factors, cytokines, and chemokines secretion. It has been shown that depletion of 
macrophages at the time of bone injury results in catastrophic failure of bone 
regeneration[238]. Macrophages have also demonstrated the ability to promote osteogenic 
differentiation and participate in both anabolic and remodeling phases[217, 239]. Because 
of these findings, macrophages have become attractive targets for bone regeneration 
therapy. Various genetic and pharmacological[240-243] approaches have been developed 
to modulate macrophages and can significantly regulate macrophage phenotypes, 
plasticity, and function.  
An important “eat me” signal expressed on the surface of apoptotic cells is the PS lipid, 
which link to the integrins on macrophages for recognition and resultant 
efferocytosis[225]. Most PS lipids have been formulated into liposome systems for 
systemic administration[227] and PS liposome treatment has shown promising effects in 
resolving inflammation and benefiting tissue repair[35, 36, 244]. However, liposome 
systems have several disadvantages, including instability in the blood stream[37], short 
half-lives,[38, 245] and off-target effects[135, 246], and are therefore not suitable for 
regenerating localized bone defects, where spatially-controlled and prolonged presentation 
of the biological factors and signal cues are required.  
In this work we hypothesize that engineered particles bearing “eat me” signals present a 
unique approach to target macrophages and harness macrophage beneficial effects in bone 
regeneration. We have designed a biomimetic biomaterials strategy, biodegradable MS 
with PS lipids immobilized on their surfaces. Biodegradable HEMA-PLLA was 
synthesized and fabricated into MS of sizes that mimicked those of apoptotic cells (1-5µm) 
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and the microsphere surfaces were then functionalized with biotin groups. Hydrophobic PS 
lipids were modified with PEG to increase the hydrophilicity and were further 
functionalized with biotin groups. Conjugation between the MS-biotin and PS-biotin was 
achieved by the addition of avidin and this process provided a versatile and highly efficient 
(~85%) conjugation to yield BAM. 
Our in vitro efferocytosis assay revealed that macrophages engulfed more BAM than 
control MS. This supported our hypothesis that macrophage efferocytosis is enhanced by 
the microsphere surface presentation of PS lipid, the “eat me” signal. We also found 
significantly increased CCL2 secretion when macrophages were co-cultured with BAM in 
vitro at both the gene and protein levels. Recent studies have shown that CCL2 functions to 
recruit mesenchymal progenitor cells during early phases of bone fracture healing[221] and 
the stimulation of CCL2 production could also result in TGF-β1-mediated recruitment of 
bone marrow cells and bone marrow-derived mesenchymal stem cells[220]. Our in vitro 
trans-well cell migration assay data confirmed that CCL2 promoted BMSC migration, 
consistent with published data. Conditioned medium collected from the co-culture of 
macrophages and BAM or control MS demonstrated that BAM induced migration of 
significantly more BMSCs than the control MS. This difference can be partially explained 
by the enhanced CCL2 secretion of macrophages after engulfment of BAM. Due to the 
ability to mediate macrophage efferocytosis, CCL2 secretion, and ultimately BMSC 
recruitment and migration, BAM have demonstrated the ability to orchestrate bone defects 
repair.  
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NF scaffolds that mimic the fine fibrous structure of bone extracellular matrix have been 
developed and shown to promote osteogenesis and biomineralization[205, 247]. 
However, it remains a critical challenge to achieve critical-sized bone defect repair without 
the addition of cells to the scaffolds[39, 248]. We hypothesized that the macrophage 
engulfment of BAM loaded in the NF scaffold would induce an influx of stem and 
progenitor cells from the surrounding native bone, marrow and periosteum to the 
scaffold and thereby would enhance and maximize the osteogenic effects of these 
scaffolds. We tested the BAM-scaffold construct in a critical-sized calvarial defect 
repair model. Eight weeks after the implantation, we found that a certain amount of 
bone was regenerated in both plain scaffolds and control MS-scaffolds, demonstrating 
the degree of osteogenesis promoted by the advantageous biomimetic NF feature of the 
scaffolds. Excitingly, the whole calvarial defect was repaired in the BAM-scaffolds. In 
order to understand the dynamic process how the BAM enhanced the osteogenic effect 
of the NF scaffold, we monitored and compared the bone regeneration process at 
different time points between the MS-scaffold and the BAM-scaffold. The µCT and 
histologic data showed that the osteogenic outcomes of the two groups started to 
differentiate since 2 weeks and BAM group significantly increased the mineral tissue 
formation. The histologic examination of the defect areas between the control MS and 
BAM allowed us to uncover the events at early stage (prior to 2 weeks), which led to the 
resultant bone formation cascade. F4/80 staining revealed that BAM, as hypothesized, 
recruited significantly more macrophages in the first week (Figure 6.5.3 C & D), which 
subsequently elevated CCL2 secretion (Figure 6.5.3 E & F). The increased CCL2 level 
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in the initial phase contributed to the influx of bone forming cells including MSCs 
(Figure 6.5.3 I & J) to the injury site and differentiated into osteoblasts or their 
precursors, promoted by the NF scaffold, evidenced by the increased OCN expression 
levels (Figure 6.5.3 G & H). The control MS-scaffold relied on the passive cell 
migration and thus resulted in limited bone regeneration similar to the scaffold alone 
group. The impaired bone repair in CCR2 KO mice in response to the BAM-scaffold 
treatment further confirmed the critical role of CCL2 in recruiting MSCs for bone 
regeneration. This biomimetic BAM strategy took advantage of the macrophage 
efferocytosis and resultant CCL2 secretion that recruited stem cell into the osteogenic NF 
scaffold microenvironment, maximizing bone tissue formation.  
6.7 Conclusion 
Recent studies have shown the important role of macrophages in supporting bone 
formation, fracture healing and remodeling and most of work focus on genetic and 
pharmacological approaches to modulate macrophages. In this study, we developed a 
biomimetic strategy to attract macrophages and utilize their therapeutic potential in bone 
regeneration. Specifically, polymeric microspheres were surface modified with PS lipid, an 
“eat me” signal, to mimic apoptotic cells. Such BAM significantly enhanced the 
macrophage efferocytosis and recruited BMSCs via increased CCL2 secretion. Cell-free 
NF PLLA scaffolds loaded with BAM substantially promoted bone regeneration in a 
critical-sized calvarial bone repair model. The recruited and enriched osteogenic 
stem/progenitor cells in the NF scaffold microenvironment, likely further differentiate into 
mature osteoblasts/ osteocytes to produce and maintain mineralized bone locally. This 
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biomaterial design presents a novel tissue engineering approach to the repair of critical-
sized bone defects without the addition of cells, and may be utilized in other macrophage-
targeting therapeutics.  
6.8 Experiment Section 
Materials: (3s)-cis-3, 6-dimethyl-1, 4-dioxane-2, 5-dione (L-lactide or LLA) and Bovine 
serum albumin (BSA) were obtained from Sigma–Aldrich Inc. (St. Louis, MO) and 
purified by recrystallization from toluene. Stannous 2-ethylhexanoate (Sn(Oct)2), 2-
hydroxyethyl methacrylate (HEMA), tris(2-carboxyethyl) phosphine hydrochloride 
(TCEP), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC),  N-hydroxysuccinimide 
(NHS), triethylamine (TEA), poly(ethylene glycol) diamine (NH2-PEG-NH2), fluorescein 
isothiocyanate (FITC), cysteine, polyvinyl alcohol (PVA), dichloromethane (DCM), 
dimethyl sulfoxide (DMSO), chloroform, methanol and albumin from bovine serum were 
purchased from Sigma–Aldrich Inc. (St. Louis, MO) and used as received. Biotin-NHS 
was purchased from Chem-Impex Int’l Inc. (Wood Dale, IL). 1,2-dipalmitoyl-sn-glycero-
3-phosphoserine, sodium salt (DPPS) was purchased from Echelon Biosciences 
Incorporated (Salt Lake City, UT). Avidin, Egg White was purchased from EMD Millipore 
Corporation (USA).  
Preparation of microsphere-biotin: The synthesis of HEMA-PLLA copolymer was 
outlined in a previous paper[133]. HEMA was used as initiator and Sn(Oct)2 was used as 
catalyst to induce the ring opening polymerization of LLA. LLA (40 mmol, 5.760 g), 
HEMA (4 mmol, 0.464 g), and Sn(Oct)2 (0.4 mmol, 0.162 g) were well-mixed in a 25 mL 
round-bottom flask under nitrogen purge and kept at 140°C for 2 h. The product was 
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cooled down and dissolved in 20 mL DCM. The polymer was precipitated out in 50 mL 
cold methanol, and then vacuum dried.  
HEMA-PLLA was formulated into microspheres (MS) using the double emulsion method. 
One ml 10 % w/v HEMA-PLLA/ DCM solution was emulsified into 20 ml PVA aqueous 
solution (1% w/v) using a probe sonicator at an output power of 10 W (Virsonic 100, 
Cardiner, NY) for 20 s to create an oil-in-water emulsion. The solution was stirred at room 
temperature for 3 hours to evaporate DCM, and then centrifuged at 6000 rpm for 6 minutes 
to collect solid microspheres. The microspheres were washed with distilled water three 
times and freeze dried. 
Excess cysteine (5 equiv), HEMA-PLLA MS (containing 1 equiv HEMA-PLLA), and 
TCEP (1 equiv) were dissolved in deionized water, then purged with N2 for 10 min and 
stirred for 2 h at room temperature. This induces click reactions between thiol groups of 
cysteine and surface alkene groups on MS. MS-cys were then washed extensively using 
deionized water and lyophilized for 2 d.  
Excess NHS-Biotin (5 equiv) was dissolved in DMSO, and then added into a MS-cys 
aqueous dispersion. The mixture was stirred for 3 h at room temperature, then washed 3 
times and freeze-dried. 
Preparation of PS-biotin: PS (1 equiv) and NH2-PEG-NH2 (1 equiv) were dissolved in a 
solution of chloroform and methanol (65:35). EDC (1 equiv) and NHS (1 equiv) were 
added to the solution and the reaction mixture was stirred at room temperature for 24 h. 
After the reaction mixture was filtered, 4 ml water was added and the mixture was 
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concentrated in a rotary evaporator to remove chloroform and methanol. The remaining 
PS-PEG aqueous solution was then freeze-dried.  
Excess NHS-Biotin (5 equiv) was first dissolved in DMSO and added into a PS-PEG 
aqueous solution. The mixture was stirred for 3 h at room temperature, transferred into a 
dialysis bag (molecular weight cut-off (MWCO) 1000 Da, Fisherbrand regenerated 
cellulose), and dialyzed against a continuous flow of deionized water for 2 days, then 
freeze-dried. 
Conjugation between microspheres and PS lipids: MS-biotin was first dispersed in water, 
then avidin was added and the mixture was stirred for 10 min. Varying amounts of PS-
biotin were then added. The ratio of avidin to PS-biotin was 1 mg avidin to 10 µg biotin. 
The mixture was stirred for additional 40 mins, and then centrifuged. The microspheres 
were washed extensively with water 5 times, and then freeze-dried.  
Evaluation of PS-biotin conjugation efficiency: The BAM were incubated in nonionic 
water at 70 C° for 5 mins to break PS-biotin bonds from the MS surfaces, then centrifuged. 
The PS-biotin amount in the supernatant was determined using Biotin Quantitation Kits 
(ThermoFisher, USA). MS conjugated with NH2-PEG-NH2 were used as control MS to 
minimize hydrophilicity difference between the control MS and BAM groups. PS to MS 
weight ratio was fixed at 1:20 in BAM experimental groups for the following experiments 
in the subsequent studies.  
NMR characterization: 1H spectra of the PS-biotin were obtained with an Inova 400 NMR 
instrument operating at 400 MHz at room temperature using deuterated chloroform 
(CDCl3) as the solvent.  
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FTIR characterization: The FTIR spectrums of MS and PS lipid before and after biotin 
functionalization were recorded with a Perkin Elmer 1800 FTIR spectroscopy, in the 
wavelength range from 600 to 4000 cm−1.  
Scanning Electron Microscopy (SEM) Observation: The microspheres were coated with 
gold using a sputter coater (DeskII, Denton vacuum Inc) and the surface morphology was 
examined using SEM (JEOL 7800FLV, USA) with an acceleration voltage of 15kVe. 
In vitro cell culture: Primary bone marrow cells were collected from 4 to 8-week old 
C57BL/6J mice. Bone marrow-derived macrophages (BMMs) were differentiated in vitro 
from bone marrow flush in α-MEM medium (10% FBS, Pen/Strep, glutamine) with murine 
M-CSF (30 ng/mL eBioscience) for 6 days. At day 7, macrophages were plated in 
3 × 105 cells/well in 12-well plates (for efferocytosis assays) or 1.0 × 106 cells/well in 6-
well plates (for protein/RNA). Bone marrow stromal cells (BMSCs) were derived from 
bone marrow flush, cultured in α-MEM medium (20% FBS, Pen/Strep, glutamine) and 
used at passage 1.  
Confocal Imaging: BMMs were plated in 1.5-mm coverglass chambers (8 × 104 cells/well) 
and stained with CellTracker DeepRed for 1 hr before efferocytosis study. Microspheres 
were then added into the wells (microspheres/macrophages=6:1). After 0.5 and 1 h co-
cultures, BMMs were fixed with ice-cold methanol for 20 mins. Cells were then washed 
with PBS and covered with ProLong® Gold antifade reagent with DAPI (Life 
Technologies). Confocal microscopy images were analyzed using the Leica inverted SP5X 
confocal microscope system with two-photon film and Leica software (Leica 
Microsystems). 
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Transmission electron microscopy (TEM) imaging: Transmission electron microscopic 
images of the BMMs were taken for both the cellular ultrastructural analysis and the 
assessment of microsphere internalization. The macrophages (1.0 × 106 cells/mL) were 
plated in 6-well plates. The BMMs were then allowed to adhere for 24 h. Next, the cell 
medium was withdrawn and replaced with α-MEM medium supplemented with 0.2 % FBS. 
Different microspheres (microspheres/macrophages=5:1) were separately added to the 
plate and incubated for 1 h. After the incubation period, the cellular medium was replaced 
by a fixative solution containing 2.5 % glutaraldehyde (0.1 mol /L), sodium cacodylate 
buffer (0.1 mol /L, pH 7.4), and calcium chloride (3 mmol /L) for 5 min at room 
temperature, followed by 1 h in an ice bath. Next, the cells were rinsed with cacodylate 
buffer/calcium chloride and were post-fixed with 1 % osmium tetroxide, cacodylate buffer 
(0.1 mol/L), calcium chloride (3 mmol/ L), and potassium ferrocyanide solution (0.8%) for 
30 min on ice. The cells were scraped off from the plate and washed with deionized (DI) 
water, then dehydrated in an ascending series of ethanol (20, 50, 70, 80%, and twice at 
100%). The cells were embedded in Epon 812 resin for 72 h and placed in an oven for 
polymerization at 60°C. The monolayer culture ultra-thin sections were stained with uranyl 
acetate and lead citrate, then transferred to uncoated copper grids and examined in a Zeiss 
LEO 902 transmission electron microscope at an accelerating voltage of 60 kV. 
Efferocytosis assay: Macrophages were stained using CellTracker DeepRed before adding 
microspheres. A total of 1.8 × 106 microspheres (microspheres/macrophages=6:1) were 
added into each well of the macrophage seeded 12-well plate (α-MEM medium, 0.2% 
FBS). After 0.5 and 1 h, BMMs co-cultured with microspheres were harvested and stained 
 91 
with F4/80-PE (Abd Serotec, CI:A3-1). The co-cultures were fixed with 1% formalin and 
efferocytosis was assessed via flow cytometric (FACs) analyses (BD FACSAriaTM III) for 
double labeled cells (FITC+ PE+) reflecting engulfment. Macrophages cultured alone 
without microspheres were used as the control. 
Gene expression and QRT-PCR: Gene expression was compared among the groups of 
BMM alone, BMM-control MS, and BMM-BAM. After 2, 6, 12, 24 h of co-culture, RNA 
was isolated using the Qiagen RNeasy Mini Kit. Reverse transcription PCR was conducted 
and the cDNA products were amplified and detected using TaqMan Universal PCR master 
mix (Applied Biosystems) and TaqMan probes. Mouse BMP2 (Mm01340178_m1), BMP7 
(Mm00432102_m1) and CCL2 (Mm00441242_m1) were used as an endogenous controls. 
Realtime PCR was analyzed on ABI PRISM 7700 (AppliedBiosystems). 
CCL2 enzyme-linked immunosorbent assay (ELISA): Supernatants were collected from 24 
h co-cultures of BMM alone, BMM-control MS, and BMM-BAM groups. CCL2 protein 
levels in culture supernatants were measured with the Quantikine mouse CCL2 ELISA 
(R&D systems) per manufacturer's instructions. The absorption values were measured 
using an EZ Read 400 microplate reader (Biochrom). 
In vitro transwell BMSC migration study: Migration assays were performed as described in 
previous studies with minor modifications[249]. Cell migration was assessed in 24-well 
plate transwells (Corning, Inc.) with a diameter of 6.5 mm and a pore size of 8 µm coated 
with 0.2 mg/mL collagen type I (EMD Millipore). BMSCs were placed in the upper 
chambers. Conditioned media from macrophage and either BAM or MS co-culture or α-
MEM medium containing CCL2 protein and 0.2% FBS were added to the lower chambers. 
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After 8 hours, cells were fixed with 2.5% glutaraldehyde for 15 minutes. Cells, which 
remained on top of transwell membranes, were removed with cotton swabs. Cells that had 
migrated through the pores to the lower surface were stained with Gill’s Hematoxylin 
(Sigma-Aldrich). Four fields at 200X magnification were selected at random, photo 
micrographic images obtained, and the cells in each image counted.  
BAM immoblized scaffold preparation: 3D NF PLLA scaffolds with inter-connected 
spherical pores were fabricated as previously described[92]. Sugar spheres of desired-size 
(250-420 µm) were collected, washed with hexane three times, and added to a Teflon mold. 
The mold was heat-treated at 37 °C for 15 min to achieve the desired inter-connected pore 
structure, then placed under vacuum to remove the hexane. PLLA/THF (10% w/v solution) 
was cast into the sugar sphere assembly and the whole construct was stored at -80 °C 
overnight to induce phase separation. The phase-separated samples were immersed in 
distilled water to extract the solvent and leech away sugar spheres, leaving behind the NF 
PLLA scaffolds which were then freeze-dried and cut into thin disks (5 mm diameter and 1 
mm thickness). BAM or control MS were immobilized onto the scaffolds via a solvent 
annealing method. Briefly, the BAM or control MS suspension was seeded onto the 
prefabricated NF PLLA scaffold, then subjected to a mixed solvent of hexane/THF 
(volume ratio of 90/10) which immobilized the BAM or control MS on the scaffold. The 
scaffolds were vacuum dried for 3 days to remove the solvent.  
Calvarial bone-defect repair: All animals were maintained in accordance with institutional 
animal care and use guidelines. Experimental protocols were approved by the Institutional 
Animal Care and Use Committee of the University of Michigan. C57BL/6J mice were 
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purchased from the Jackson Laboratory, Bar Harbor, ME and CCR2 knockout (CCR2 KO) 
mice were received from Prof. Beth Moore lab, University of Michigan. Mice were 
randomly divided into experimental groups. Animals were anesthetized with isoflurane 
(2%) inhalation. A 5-mm craniotomy defect centered on the parietal calvarial bone was 
created using a trephine. A scaffold was placed to fill the defect (blank, control MS and 
BAM). The mice were euthanized at designated time points after implantation and the 
skulls were harvested. 
µCT reconstruction and analysis: The skulls were placed in a 34 mm diameter specimen 
holder and scanned using a microCT system (µCT100 Scanco Medical, Bassersdorf, 
Switzerland). Scan settings were: voxel size 18 µm, 70 kVp, 114 µA, 0.5 mm AL filter, 
and integration time 500 ms. Analysis was performed using the manufacturer’s evaluation 
software, and a fixed global threshold of 18% (180 on a grayscale of 0–1000) was used to 
segment bone from non-bone. 3D reconstruction of the skull and quantitative analyses 
were performed. A 5-mm round region of interest centered on the defect was determined 
and the bone volume (mm3) (BV) and bone mineral density (BMD) in the area were 
measured using manufacturer's software (Scanco µCT 100).  
Bone histologic and histomorphometric analysis: Calvarial samples were fixed with 4% 
formalin, decalcified with 10% EDTA for 2 weeks and subsequently embedded in paraffin. 
Hematoxylin & eosin (H&E) staining of the coronal sections (5 µm thick) were performed 
by the histology core at the University of Michigan, School of Dentistry. To visualize 
F4/80 positive cells, the de-paraffinized slides were incubated overnight at 4 °C with a 
mouse polyclonal primary antibody to F4/80 (1:100, ab6640 Abcam) and staining was 
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performed using the standard Anti-Rat HRP-DAB Cell & Tissue Staining Kit (R&D) 
following the manufacturer's protocol. For immunofluorescence visualization of OCN and 
CCL2 expression within the defect areas, the slides were de-paraffinized and heat treated 
in the citrate buffer (2.1 M citric acid, pH 6.0) at 100 °C for 30 min for antigen retrieval. 
After blocking in 3% BSA/PBS solution, sections were then incubated overnight at 4 °C 
with a rabbit polyclonal primary antibody to OCN (1:100, ab93876 Abcam) or a rabbit 
polyclonal primary antibody to MCP1 (1:100, ab25124 Abcam). After three washes in PBS, 
the sections were incubated with TRITC-conjugated donkey antibody to rabbit IgG (1:400, 
Santa Cruz) for 1 h. To visualize the CD73 and CD105 expressing cells, slides were 
incubated overnight at 4 °C with Polyclonal Sheep antibody to Mouse 5'-
Nucleotidase/CD73 (1:100, AF4488 
, R&D system) and Polyclonal Goat antibody to Mouse Endoglin/CD105 (1:100, AF1320, 
R&D system), after de-paraffinized, blocked in 3% BSA/PBS solution. After three washes 
in PBS, the sections were incubated with TRITC-conjugated donkey antibody to goat IgG 
(1:400, sc3885, Santa Cruz) and FITC-conjugated rabbit antibody to sheep IgG (1:400, 
#31627, ThermoFisher) for 1 h. The sections were mounted with the medium containing 
DAPI (Vector Laboratories) and then examined under a confocal microscope (Eclipse C1 
Plus, Nikon).  
Static histomorphometric analyses for F4/80 positive cell number and CCL2 and OCN 
expression were performed using computer-assisted histomorphometric analyzing software 
(Image-Pro Plus version 4.0; Media Cybernetics, Inc., Silver Spring, MD and NIS-
Elements AR, Nikon.). 
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Statistical Analysis: All numerical data are presented as mean ± SD. All P values were 
two-tailed and P < 0.05 was considered statistically significant. One-way ANOVA test was 
applied to compare different groups using GraphPad InStat software (GraphPad). 
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CHAPTER 7 
Conclusion and Outlook 
 
7.1 Conclusion 
In this thesis, we have developed two biomimetic systems and use them as platform 
technologies to explore the regenerative potential of PTH delivery and apoptotic-cell 
mimicking microspheres in bone tissue engineering applications.  
Preprogrammed PTH delivery system 
Implantable preprogrammed drug delivery devices have been developed with the ability to 
release PTH in pulsatile and continuous fashions. For the pulsatile delivery device, surface 
erosion polymer has been synthesized and advanced fabrication techniques have been 
developed to enable us to fabricate the pulsatile delivery device capable of delivering 
multiple pulses of PTH.  The release kinetics can be modulated via tuning the both 
chemical and physical properties of the device. We achieved 21-pulse PTH release with 
different time intervals (ranging from 24 hours to 60 hours) and over 90% drug bioactivity 
can be maintained. For the continuous delivery device, we prepared surface-erosion 
microspheres capable of sustained PTH release in a linear manner, which has not been 
demonstrated with other types of biodegradable polymers. The release rate can be 
controlled via adjusting the properties of the surface erosion polymer. We demonstrated 
linear drug release for 3 weeks with over 85% drug bioactivity retained.  
Both pulsatile and continuous delivery device loaded with same amount of PTH were first 
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tested in a subcutaneous implantation model. We examined the systemic therapeutic effects 
of the engineered PTH release on vertebrae and tibia and the results showed that pulsatile 
PTH release was able to increase bone via enhancing bone remodeling, whereas the 
continuous PTH release resulted in bone resorption via elevated osteoclast resorption 
activity. The devices were biodegradable and biocompatible in vivo, eliminating the need 
for removal surgery. Therefore the biodegradable pulsatile PTH delivery device has 
demonstrated the potential to be a patient-friendly PTH therapy, which could be 
administered only once (implantation) in contrast to the current daily injection treatment.  
Further, we repurpose PTH in a local bone defect model to expand the application of PTH 
from systemic osteoporosis treatment to local bone defect repair. The delivery device 
locally releases PTH to a cell-free biomimetic NF scaffold. This combination system (PTH 
delivery device and scaffold) enabled us to determine the optimal release kinetics (pulsatile 
vs continuous) in terms of osteogenic outcome. We found that local continuous PTH 
release inhibited, while local pulsatile PTH release (daily pulse for 21 days) promoted bone 
regeneration. In addition, the local pulsatile delivery strategy advantageously achieved 
higher quality regenerated bone and reduced the systemic side effects compared to the 
standard PTH injection treatment. This is the first time local pulsatile PTH delivery has 
been achieved to promote bone regeneration via enhanced bone remodeling. This acellular 
therapy provides a novel strategy to improve bone defect repair by integrating a 
biomimetic scaffold and an anabolic local delivery to maximize the regenerative effects 
within the intended areas of interest. This technology holds promise for bone defect repair 
without addition of external cells, the burden of daily PTH injections, and the need for 
device removal surgery.  
Biodegradable Apoptotic-cell Mimicking Microspheres 
The unique role of macrophages in supporting bone formation, fracture healing and bone 
remodeling has drawn a lot of attention. In this study, we developed a biomimetic strategy 
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to target macrophages and enhance their therapeutic functions in promoting bone 
regeneration. Specifically, biodegradable polymeric microspheres were surface modified 
with “eat me signal” lipid molecules, to mimic apoptotic cells. A novel bioconjugation 
strategy has been developed to enable efficient and controlled conjugation between the 
functionalized microsphere surface and the PS lipids. This strategy overcomes the 
drawbacks of the conventional lipid liposome formulation and achieved controlled surface 
presentation of the lipid signal molecules. Several significant advantages of this strategy 
also include that the fabrication was conducted in mild aqueous and RT conditions; 
chemicals involved in these reactions have already been used in FDA-approved products. 
We evaluated BAM microspheres biological function and their interaction with 
macrophages both in vitro and in vivo. We found that BAM microspheres significantly 
enhanced the macrophages phagocytosis and induced BMSCs migration via increased 
secretion of CCL2. Cell-free NF PLLA scaffolds loaded with BAM microspheres 
substantially promoted bone regeneration in a critical-sized calvarial bone repair model. 
BAM enhanced macrophage-mediated stem cells recruitment to the NF scaffold 
microenvironment and helped induce osteoblast differentiation and biomineralization, 
thereby enhancing the osteogenic outcome in the NF scaffold. 
7.2 Future Work and Outlook 
There are numbers of future directions these systems developed here could lead to. 
Preprogrammed delivery system 
In this thesis, we demonstrated long-term preprogrammed PTH release for both systemic 
and local delivery applications. Besides PTH, more therapeutics (small molecule drugs and 
biologics) could be readily incorporated into these devices. The preprogrammed systems 
could enable delivery of multiple molecules in a simultaneous or sequential manner to 
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better replicate and regulate the natural healing process, which often involves sequential 
signaling of multiple types of biomolecules. Therefore these systems could provide more 
qualitative and quantitative understanding of the complex interaction and cooperative 
signaling between the signal molecules, microenvironment and physiology.  The 
information and the drug delivery toolbox could further provide guidance to design optimal 
personalized treatment. Beyond the tissue engineering application, we expect the platform 
(continuous and pulsatile devices) to be useful in other fundamental and translational 
studies on how temporal effects and release patterns of biomolecules regulate cell activity, 
tissue development, and physiology.  
Biodegradable Apoptotic-cell Mimicking Microspheres 
Novel chemical modification and conjugation methods have been developed to 
functionalize biodegradable microsphere with lipid signal molecules. Besides lipids 
conjugation, the functional microspheres would be readily modified with other types of 
molecules (like peptides, proteins, and antibodies). Therapeutics can be readily loaded into 
the BAM microspheres so that BAM microspheres can also serve as drug vehicle targeting 
macrophages. As we have demonstrated the BAM microspheres could promote BMSCs 
migration and further benefit the bone defect repair. We expect in the future this 
biomimetic immunomodulatory strategy opens a novel avenue to bone and potential other 
tissue regeneration without the need for exogenous cells. 
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